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Abstract 
 
Peroxisome proliferator activated receptor γ coactivator 1α (PGC-1α) is a transcriptional coactivator 
involved in mitochondrial biogenesis, oxidative stress response, and energy metabolism. PGC-1α is 
part of an energy sensing network that translates environmental influences into alterations in gene 
expression of mainly mitochondrial molecular pathways. A role in neuroprotection has been 
implicated for PGC-1α in the context of mitochondrial expression networks. 
 
Our research group has previously established a transgenic mouse line with stable overexpression 
of PGC-1α in brain neurons. Transgenic overexpression of PGC-1α is associated with an enhanced 
functional state of mitochondrial energy production. In the context of neurodegenerative processes, 
brain neurons of PGC-1α transgenic mice are protected against oxidative stressors in the MPTP 
mouse model of Parkinson’s Disease. 
 
To further characterize the transcriptional activity of PGC-1α regulated gene networks in brains of 
transgenic mice, a quantitative real-time PCR based system was established. Gene expression 
was measured for a subset of genes found to be differentially regulated in a microarray based 
screening of RNA obtained from hippocampus and cortex of PGC-1α transgenic mice. 
 
Increased PGC-1α gene expression was found in hippocampus and cortex of PGC-1α transgenic 
mice, and their translation into protein was confirmed immunohistochemically. Expression analysis 
revealed significant changes in mRNA levels of PGC-1α controlled molecular pathways involved in 
mitochondrial energy production and antioxidant responses. Furthermore, alterations in the 
expression of some non-mitochondrial genes with established links to neurodegeneration were 
observed. Furthermore, a change in GABAA receptor subunit expression was detected. 
 
In accordance with previous studies on the PGC-1α transgenic mouse line, these findings suggest 
that differential gene expression associated with PGC-1α overexpression contributes to an 
enhanced functional state of neurons in hippocampus and cortex of PGC-1α transgenic mice. 
 
Increased knowledge about the transcriptional modulation of neuronal genes regulated by PGC-1α 
can lead to better insights into mechanisms governing neurodegeneration and neuroprotective 
pathways. Pharmacological modulation of PGC-1α activity may be a feasible approach for 
neuroprotective treatments in neurodegenerative diseases, such as Parkinson’s Disease. 
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PGC-1, qPCR 
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Abbreviations 
– qPCR program run without extension time during the amplification step 
+ qPCR program run with extension time during the amplification step 
°C degrees Celsius 
Acetyl-CoA Acetyl coenzyme A 
Acly Citrate lyase 
ADP Adenosine diphosphate 
AMPK AMP (adenosine monophosphate)-activated kinase 
AS antisense 
Atg3 Autophagocytosis associated protein 3 
ATP Adenosine triphosphate 
Atp5h ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d 
cAMP Cyclic adenosine monophosphate  
cDNA Complementary DNA  
CoQ Coenzyme Q 
Cox5b cytochrome c oxidase, subunit Vb 
Cox7b cytochrome c oxidase, subunit VIIb 
COXIV cytochrome c oxidase, subunit IV 
Cp quantification cycle 
CREB cAMP response element binding protein 
Cx cortex 
CytC cytochrome c 
DA dopaminergic 
dH2O distilled water 
DNA deoxyribonucleic acid 
dNTP deoxynucleotide 
E Efficiency value 
ERR α Estrogen-related receptor 
ETC Electron transport chain 
ETS  electron transport system 
FADH oxidized flavin adenine dinucleotide 
FADH2  reduced flavin adenine dinucleotide 
GABA aminobutyric acid 
GABAA aminobutyric acid receptor A 
Gabra2 GABAA receptor subunit 2 
Gabrg2 GABAA receptor subunit 2 
GCN5 Lysine acetyltransferase 2A 
GSH reduced glutathione 
Gsr Glutathione reductase 
GSSG oxidized glutathione 
Hc Hippocampus 
IHC immunohistochemistry 
IMM inner mitochondrial membrane 
mg milligram 
mM millimolar 
mm millimeter 
M-MLV Modified murine leukemia virus 
MnSOD superoxide dismutase 
MPP+ 1-methyl-4-phenylpyridinium 
MPTP 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridin 
mRNA messenger RNA 
mTOR Mammalian target of rapamycin 
NAD
+
 oxidized nicotinamide adenine dinucleotide 
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NADH reduced nicotinamide adenine dinucleotide 
Ndufa13 NADH dehydrogenase 1 alpha, subcomplex 13 
Nedd8 Neural precursor cell expressed, developmentally down-regulated 8 
NeuN Rbfox3 RNA binding protein, fox-1 homolog (C. elegans) 3 
NRF-1 Nuclear factor 1 
NRF-2 Nuclear factor 2 
PBS phosphate buffered saline 
PBS-T phosphate buffered saline, supplemented with Triton-X 
PCR Polymerase chain reaction 
PD Parkinson’s Disease 
PGC-1α Peroxisome proliferator activated receptor γ coactivator 1α 
PKA protein kinase A 
PPARα peroxisome proliferator activated receptor α 
qPCR quantitative real-time polymerase chain reaction 
R relative expression ratio 
Rheb Ras homolog enriched in brain 
RNA ribonucleic acid 
ROS Reactive oxygen species 
rpm revolutions per minute 
RSV resveratrol 
S sense 
Sirt-1 Sirtuin 1 (silent mating type information regulation 2, homolog) 
SNc substantia nigra pars compacta 
SOD2 superoxide dismutase 2 
Stdev standard deviation 
tg transgenic 
Trx2 thioredoxin 2 
TrxS- oxidized thioredoxin 
TrxSH reduced thioredoxin 
Uba3 ubiquitin-like modifier activating enzyme 3 
UPS ubiquitin-proteasome system 
wt wildtype 
μg microgram 
μl microliter 
μm micrometer 
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1. Review of the literature 
1.1. Mitochondria 
1.1.1. Mitochondrial energy metabolism 
1.1.1.1. ATP production via cellular respiration 
Mitochondria are cytosolic cell organelles harboring a number of the cell’s most 
essential pathways for survival and energy metabolism. Mitochondria are critically 
involved in energy metabolism, being the site of adenosine triphosphate (ATP) 
production, and housing the pathways that regulate energy expenditure and storage 
on the level of the whole organism. Reviewed in (Duchen 2004, Nunnari, 
Suomalainen 2012) 
One of the main functions of mitochondria is production of energy in form of ATP 
via oxidative phosphorylation in the electron transport chain (ETC) in a process 
known as cellular respiration. The ETC is a sequence of large enzyme complexes, 
whose subunits are encoded in a concerted way by the mitochondrial and nuclear 
genomes. As shown in figure 1, the enzymes are located within and spanning the 
mitochondrial inner membrane. Reviewed in (Duchen 2004, Nunnari, Suomalainen 
2012, Abou-Sleiman, Muqit & Wood 2006, Schon, Przedborski 2011) 
 
 
Figure 1 The mitochondrial electron transport chain. Shown here is the mitochondrial electron transport chain 
with electron transporting complexes I to IV and F1FO ATP synthase (complex V), the site of ATP production. 
Electrons are transported down the electron transport chain from complex I to IV, where they are transferred 
to oxygen to produce water. Redox reactions along complexes I to IV are building up a proton gradient that is 
used at complex V as driving force for phosphorylation of ATP. ETS: electron transport system, IMM: inner 
mitochondrial membrane, CoQ: coenzyme Q, Cyt C: cytochrome c. Reprinted by permission from Macmillan 
Publishers Ltd: Nature reviews. Neuroscience, (Abou-Sleiman, Muqit & Wood 2006) 
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The ETC function is based on the flow of electrons provided via metabolism of 
different nutrients. Breakdown of carbohydrates, proteins, and fatty acids results in 
production of acetyl coenzyme A (Acetyl-CoA), which enters the citric acid cycle. 
Via the citric acid cycle, metabolic pathways are integrated to yield the oxidized 
forms of the high energy compounds nicotinamide adenine dinucleotide (NADH) 
and flavin adenine dinucleotide (FADH2). Both molecules act as electron carriers, 
and transfer electrons to ETC complexes I and II, respectively. Sequential transfer of 
energy in form of the received electrons along ETC complexes I to IV results in a 
series of redox reactions. At the end of a gradual oxidation of the ETC enzymes, 
electrons are transferred to molecular oxygen, resulting in reduction to water. With 
exception of complex II, the enzymes make use of the energetic flow to transfer 
protons across the inner membrane and into the inter-membrane space. Ultimately, 
the ETC enzymes’ activity thereby generates a proton gradient across the 
mitochondrial inner membrane. (Duchen 2004) 
This electrochemical gradient is utilized by complex V, the F1Fo ATP synthase. The 
energy of a controlled backflow of electrons across the inner membrane allows 
complex V to generate ATP by phosphorylation of adenosine diphosphate (ADP). 
(Duchen 2004, Nunnari, Suomalainen 2012) ATP is redistributed throughout the cell 
to provide energy. (Schon, Przedborski 2011) 
 
1.1.1.2. Regulation of mitochondrial energy metabolism 
The activity of the ETC, reflecting the level of cellular respiration, is adapted to 
match the energetic needs of single cells as well as the whole organism. The ability 
of the mitochondrial respiratory chain to respond to alterations in the energy status, 
reflected by the ADP concentrations, and adapt the rate of ATP production to the 
energetic needs, is termed respiratory control. The regulatory mechanisms are 
coupled to the proton gradient across the mitochondrial inner membrane, and 
influenced by the availability of ADP, the energetic status and need for energy. 
Reviewed in (Duchen 2004, Nunnari, Suomalainen 2012) 
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1.1.2. Oxidant production and antioxidant system 
During cellular respiration, reactive oxygen species (ROS) are generated as a by-
product of electron transport chain activity. Leakage of unpaired electrons occurs 
during oxidative phosphorylation, mainly at complexes I and III. As a consequence 
of reactions between free electrons and oxygen, superoxide ions are generated. These 
are highly reactive oxidants, and can, in turn, be converted to other radical species 
and promote further formation of oxidants. (Nunnari, Suomalainen 2012, 
Kowaltowski et al. 2009, Turrens 2003) 
 Oxidants react with and thereby damage intracellular macromolecules, such as 
membrane lipids or DNA (deoxyribonucleic acid). Defects due to oxidative reactions 
can severely impair mitochondrial function and disturb the intracellular homeostasis. 
(Duchen 2004, Balaban, Nemoto & Finkel 2005, St-Pierre et al. 2006) 
Mitochondria are the main producers of ROS, as well as the main targets of 
oxidative damage. Pronounced and sustained increases in respiratory activity can 
therefore entail a disturbance of the oxidant status, due to increased production of 
ROS.  
In a physiological and functional state, mitochondria possess a well-developed 
system that allows them to scavenge most of the ROS before they can cause damage. 
An elaborate system of antioxidant defense mechanisms intrinsic to mitochondria 
scavenges the reactive molecules generated during cellular respiration (figure 2 
shows a summary of the antioxidant systems immediately scavenging ROS). Among 
these defense systems, the most prominent are glutathione, superoxide dismutases, 
thioredoxin, and catalase. Acting on different stages of oxidant production allows 
these systems to maintain a low level of oxidants. (Duchen 2004, Kowaltowski et al. 
2009, Turrens 2003, Lin, Beal 2006)  
Glutathione, for example, serves to scavenge reactive oxidant species by reducing 
them to a more stable state, thereby preventing them from reacting with and 
damaging other intracellular molecules. This process leads to oxidation of 
glutathione and formation of glutathione disulfide. The functionality of the 
glutathione antioxidant system is regenerated by the enzyme glutathione reductase 
that maintains the pool of glutathione in a steady-state. (Nicholls 2002) 
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In addition, mitochondrial uncoupling proteins can partly dissipate the proton 
gradient, allowing protons to cross the membrane independently of ATP production. 
By reducing the electrochemical gradient, uncouplers decrease the production of 
ROS via the respiratory chain complexes. (Duchen 2004, Andrews, Diano & 
Horvath 2005) 
 
Figure 2 Mitochondrial oxidant production, antioxidant systems and ROS scavenging. Complexes I and III are 
the main sites of reactive oxygen species (ROS) production. Shown here are the main steps in ROS scavenging in 
immediate proximity to the electron transport chain. ROS are dismutated by MnSOD superoxide dismutase. The 
main immediate ROS scavengers are catalase, and the peroxidases thioredoxin peroxidase and glutathione 
peroxidase. Antioxidants thioredoxin and glutathione are oxidized to buffer ROS, and reductases (thioredoxin 
reductase, glutathione reductase) maintain the functionality of antioxidants. GSH: reduced glutathione, GSSG: 
oxidized glutathione, MnSOD: superoxide dismutase, TrxSH: reduced thioredoxin, TrxS-: oxidized thioredoxin. 
Reprinted by permission from Macmillan Publishers Ltd: Free radical biology & medicine., (Kowaltowski et al. 
2009) 
 
1.2. Role of mitochondria in neurodegenerative diseases, as exemplified by   
Parkinson’s Disease 
1.2.1. Parkinson’s Disease 
1.2.1.1. Clinical features of Parkinson’s disease  
Parkinson’s disease (PD) is a neurodegenerative disorder predominantly affecting 
dopminergic neurons of the nigrostriatal pathway. This midbrain pathway connects 
the striatum to substantia nigra pars compacta (SNc) and is important for the 
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initiation of voluntary movements. Degeneration of the nigrostriatal pathway results 
in a decreased dopaminergic input to the striatum, complicating movement 
coordination.  
Due to the importance of this pathway’s functionality in movement initiation, 
movements of PD patients typically appear slow and rigid. Further clinical 
symptoms of PD are resting tremor, postural instability, and bradykinesia. Common 
non-motor symptoms are autonomic and cognitive dysfunction. More rarely, patients 
also develop psychological symptoms, such as depression and dementia.  Reviewed 
in (Jankovic 2008, Poewe 2008, Schapira et al. 2009, Dexter, Jenner 2013) 
Preclinical symptoms with an onset earlier during disease progression are rather 
unspecific and therefore often remain unrecognized or undiagnosed for a long time. 
In most cases, the clinical symptoms only become overt when up to 60% of 
dopaminergic (DA) neurons of the nigrostriatal pathway have already been lost. At 
this time point, neurodegenerative processes have been progressing for years or even 
decades. (Dauer, Przedborski 2003, Schapira 2009)   
This delay in diagnosis hampers effective treatment, since neurons, once lost, cannot 
be replaced or regenerated with the currently used treatments. Dopamine-
replacement therapies, such as levodopa-administration, are to date the gold standard 
of PD medication. However, they can alleviate the symptoms only for a limited time 
frame, without being able to actually protect the remaining neuronal population from 
degeneration or restore neuronal capacity that has already been lost. With these 
merely symptomatic treatments, it is at present impossible to restore functionality of 
the nigrostriatal system. To date, there is no curative treatment for PD 
neurodegeneration. (Dexter, Jenner 2013) In order to improve the outcome, it would 
be crucial to start treatments already early in disease progression. The second 
challenge is the development of neuroprotective drugs – this approach then could 
slow or possibly even halt the demise of neurons. (Schapira 2009) 
 
1.2.1.2. Molecular pathogenesis of Parkinson’s Disease 
In PD pathogenesis, DA neurons of the nigrostriatal pathway undergo cell death in a 
dying back process: degeneration of neuron terminals in the striatum is followed by 
demise of cell bodies located in SNc. (Dauer, Przedborski 2003) 
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There is no single cause for this degenerative process and its specificity for the 
nigrostriatal pathway. Rather, a cascade of events under mutual influence affects the 
functionality of this neuronal population. (Jenner, Olanow 2006) To date, it is not 
known which of the events involved in neuronal death is to be considered the initial 
trigger for degeneration, if this first step towards disease progression exists at all. 
Rather, findings have been pointing towards a more integrative explanation. (Jenner, 
Olanow 2006) 
There are a number of specific defects that have been associated with Parkinsonism: 
Mutations in a number of genes have been identified in association with familial 
cases of PD, such as α-synuclein or parkin. The disruption of cellular functions 
caused by those mutations is causative for Parkinsonism. (Thomas, Beal 2007, 
Thomas, Beal 2011) 
Moreover, several neurotoxins have been reported to cause Parkinsonism in a 
clinical context, and are also used to model Parkinsonism in animal models. 
(Betarbet et al. 2000, Przedborski et al. 2004) Interestingly, most of the gene 
mutations and neurotoxic assaults target processes involved in mitochondrial 
function.  
Apart from these specific assaults, age is the most influential contributor to PD risk. 
The reasons for this are still not fully understood, but numerous factors also known 
to be contributing to the physiological aging process are involved in 
neurodegeneration in general and neuronal demise in PD, in particular. (Beal 2005) 
Strikingly, most of the pathways considered contributors to neurodegenerative 
processes are linked to mitochondria.  
It has been proposed that decreasing mitochondrial functionality is one of the most 
important key factors promoting disease risk. (Lin, Beal 2006)  Mitochondrial 
metabolism, oxidative state and biogenesis are emerging as pivotal influences on 
neuronal functionality. In case of a deregulation of the tightly maintained 
homeostasis, these processes can turn into triggers for neuronal dysfunction and 
severely disturb mitochondrial and neuronal functionality. Impaired functionality, in 
turn, contributes to further accumulation of cellular damage, and neurons enter a 
cycle of progressive damage. Ultimately, this interferes with the cells’ ability to 
maintain a functional state, and leads to neuronal death. (Dauer, Przedborski 2003)  
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The cause of degeneration of DA neurons in the nigrostriatal pathway is thought to 
be impaired functionality of a number of interconnected and tightly linked processes 
and, most importantly, the mutual influences among these processes. The 
dysregulations and nonfunctional state of these pathways seem to be cause and 
consequence at the same time – disturbances in either of the pathways is reinforced 
by previous disruptions of the functional state. These disturbances, in turn, further 
propel the derangement of cellular homeostasis. Regardless of what the initial 
pathogenic event has been, over the course of disease development, neurons are 
trapped in a spiral of increasing and self-promoting disruption of homeostasis and 
damage. (Jenner, Olanow 2006, Thomas, Beal 2007) 
Among the most prominent contributors to cell death in PD are mitochondrial 
dysfunctions. However, a number of processes not linked to mitochondria are 
involved in pathogenesis as well. (Jenner, Olanow 2006, Thomas, Beal 2007, Jenner 
2003) In the following sections, I am going to review the main mitochondrial and 
non-mitochondrial factors that together unsettle the functional state of neurons.  
 
1.2.2. Mitochondria in neurodegenerative pathogenesis 
1.2.2.1. Importance of mitochondria in neurons 
With their functions in energy metabolism, antioxidant systems and regulation of 
cell death, mitochondria are crucial for all cells. Some characteristics of neurons, 
however, make them even more dependent on mitochondrial processes.  
First of all, the high energy demands and metabolic activity typical for neurons have 
to be met constantly. In addition, most of the ATP consumed by neurons is generated 
through oxidative metabolism, using glucose. For these reasons, neurons are 
critically dependent on mitochondrial ETC activity and energy production. This 
energetic profile and high respiratory activity entails the production of large 
quantities of ROS via the ETC. As a consequence, the mitochondrial antioxidant 
system has to be maintained in a highly functional state to ensure constantly low 
ROS levels. (Nicholls et al. 2007) 
In addition, neuronal signaling processes depend on the maintenance of tightly 
regulated balances in ion concentrations, such as calcium, involved in synaptic signal 
transmission and regulated by mitochondrial buffering. These processes are 
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particularly important and have to be kept at a tightly regulated balance in neurons.   
(Nicholls et al. 2007, Murphy, Fiskum & Beal 1999, Arduino et al. 2010) 
 
1.2.2.2. Mitochondrial processes in neurodegenerative pathogenesis 
For the reasons reviewed above, neurons are more vulnerable towards disturbances 
in the balance regulating mitochondrial functions and cellular homeostasis.  
In case of pronounced increases in production of ROS during cellular respiration, the 
mitochondrial antioxidative defense mechanisms are overwhelmed and oxidants 
accumulate. This state is known as oxidative stress, and characterized by the 
presence of higher than normal amounts of ROS. The surplus of oxidants in the cell, 
in turn, causes further oxidative reactions harming macromolecules. Cells enter a 
cycle of ever increasing damage, while the ability to scavenge oxidants is 
progressively being impaired. At long last, this processes amounts to a dysfunctional 
state of mitochondrial energy production. (Murphy, Fiskum & Beal 1999) 
Under conditions of bioenergetic failure, oxidative stress impairs mitochondrial 
processes involved in energy metabolism, and in particular, the respiratory chain. 
The functionality and efficiency of ATP production via the electron transport chain 
is impaired, predominantly due to oxidative damage to complex I. This complex is 
among the main sites of electron leakage, and, especially in an impaired functional 
state, propels the production of ROS. (Betarbet et al. 2000) As a consequence, the 
electrochemical gradient maintained by means of managing proton concentrations on 
either side of the mitochondrial inner membrane cannot be kept at a stable level. The 
membrane tends to depolarize and the proton gradient partially dissipates. This 
causes a drop in the driving force for ATP production, and the energy metabolism 
via oxidative phosphorylation cannot be maintained on a level sufficient to meet the 
needs of the cell and organism. Bioenergetic failure links energy metabolism and 
oxidative stress. Together, these impairments lead to a state of mitochondrial 
dysfunction. Ultimately, this entails severe disturbances within the cellular 
functionality, leading to cell death. (Schon, Przedborski 2011, Beal 2003, Schulz et 
al. 2000) 
Furthermore, cellular pathways involved in the regulation of recycling of 
dysfunctional cell components, cell death and survival are affected during disease 
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progression. (Abou-Sleiman, Muqit & Wood 2006) Autophagy, the process of 
lysosomal degradation of organelles, has been implicated in neurodegeneration. 
Nonfunctional cell organelles are taken up into autophagosomes. Subsequently, 
autophagosomes fuse with lysosomes, where organelles are degraded or partially 
recycled. Autophagy is regulated via protein modifications, and influenced by a 
number of signaling pathways also involved in regulation of cellular survival, for 
example in mammalian target of rapamycin (mTOR) signaling. (Kim, Rodriguez-
Enriquez & Lemasters 2007, Lee, Giordano & Zhang 2012) 
In addition, glutamate mediated excitotoxicity contributes to the demise of neurons 
in PD. Excitotoxicity is defined as a pronounced overstimulation of neurons via 
glutamate-signaling. Excessive calcium-influx entails disturbances in several cellular 
processes and damage to macromolecules. Eventually, these disturbances trigger 
apoptotic cell death. (Jenner, Olanow 2006, Blandini 2010) 
Disturbances of homeostasis in several cellular processes render neurons more 
vulnerable to excitotoxic assaults. Under oxidative stress conditions, neurons are 
more likely to undergo calcium overload. The balance of intracellular calcium levels 
becomes more fragile, and in case of even mild glutamatergic overstimulation, the 
depolarization balance can easily be tilted towards initiation of excitotoxic cell death. 
This process is linked to mitochondria, which have an important role in maintaining 
the calcium homeostasis. (Duchen 2004, Blandini 2010, Atlante et al. 2001, Beal 
1998, Meredith et al. 2008, Meredith et al. 2009, Surmeier et al. 2011)  
Under conditions of increased oxidative stress, the ubiquitin-proteasome system 
(UPS), which controls the degradation of misfolded and nonfunctional proteins, is 
overloaded by the large amount of damaged molecules. In a healthy state, the UPS 
serves to identify and scavenge misfolded or otherwise nonfunctional proteins. If 
refolding into the appropriate conformation by chaperones does not succeed, 
damages proteins are degraded via the proteasome. A histological hallmark of PD is 
the presence of Lewy bodies, inclusions of α-synuclein in the cytoplasm of affected 
neurons. Again, it is not known whether these inclusions contribute to 
neurodegeneration or serve as a storage compartment for misfolded proteins. 
(Thomas, Beal 2011, Moore et al. 2005, Schapira 2008) 
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An additional process triggered by increased oxidative conditions is inflammation. 
During late stages of disease progression, inflammation further increases the 
oxidative stress in the remaining neurons’ environment. (Surmeier et al. 2011, 
Schapira 2008, Cohen, Farooqui & Kesler 1997, Cohen 2000, Cowell, Blake & 
Russell 2007, Tritos et al. 2003) 
DA neurons are thought to be affected by the initial increase in oxidative stress 
levels more than other cells, among other reasons due to excessive oxidant 
production as a byproduct of dopamine metabolism. (Lotharius, Brundin 2002) After 
onset of neuronal demise, remaining functional DA neurons compensate with 
increased dopamine production in order to maintain the functional state of the 
nigrostriatal system. Increased dopamine turnover via monoamine oxidase, in turn, 
entails even further increase in oxidant production. (Zigmond, Hastings & Perez 
2002, Brotchie, Fitzer-Attas 2009, Spina, Cohen 1989) 
Taken together, oxidative stress and mitochondrial dysfunction are emerging as 
important contributors to degeneration of neurons in PD. All of the pathways 
reviewed above are linked and contribute to PD pathogenesis in a concerted way. 
(Jenner 2003, Murphy, Fiskum & Beal 1999, Cohen 2000, Jenner 2004) 
Ultimately, the interactions and mutual influences of the factors reviewed above may 
determine the way in which the tightly regulated homeostasis among numerous 
pathways is disturbed and gradually unsettle the physiological state of neurons. 
(Jenner, Olanow 2006) This again may be decisive for the vulnerability of particular 
cell populations, and, together with their biochemical and metabolic properties, 
target as well as restrict the demise of cells in PD to the particular population of DA 
neurons of the nigrostriatal pathway. (Cohen, Farooqui & Kesler 1997, Cohen 2000, 
Cohen, Kesler 1999a, Cohen, Kesler 1999b) 
Together with the unique signaling properties of the nigrostriatal system, the 
interplay of disturbances in mitochondrial pathways affecting metabolism, oxidant 
production and scavenging may be one of the crucial factors conferring specificity to 
the neurodegenerative assaults. Initial disturbances may tip the well-balanced system 
of interlaced processes and pathways, causing an ever increasing and self-enhancing 
amount of oxidative stress and neuronal demise. The current view on pathogenesis 
assumes a number of events under mutual influence that lead to neuronal 
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degeneration in a concerted way. Rather than being caused by a single pathogenic 
event, neuronal degeneration results from a “circle” of events that all seem to be 
cause and consequence of neuronal demise at the same time – this underlines the 
complexity of pathogenic processes and shows how the neuronal physiology is 
profoundly disturbed. (Jenner, Olanow 2006, Jenner 2003, Surmeier et al. 2011, 
Lotharius, Brundin 2002) 
At the intersection of the processes reviewed above, the transcriptional coactivator 
PGC-1α is emerging as the pivotal point controlling and integrating mitochondrial 
biogenesis and metabolism with the energetic and oxidative state of the cell. (Zheng 
et al. 2010) 
 
1.3. Peroxisome proliferator activated receptor γ coactivator 1α (PGC-1α) 
1.3.1. PGC-1α as a master regulator of mitochondrial pathways  
Peroxisome proliferator activated receptor γ coactivator 1α (PGC-1α) is a 
transcriptional coactivator, and a master regulator of mitochondrial biogenesis, 
oxidative stress response, and, with its role in regulating respiration, of energy 
metabolism and homeostasis. (Kelly, Scarpulla 2004, Puigserver et al. 1998) 
reviewed in (Puigserver, Spiegelman 2003) 
PGC-1α is a member of the PGC-1 coactivator family comprising some of the main 
regulators of adaptive responses to metabolic cues and environmental influences. 
The PGC-1 coactivators, and in particular PGC-1α, are in the center of a regulatory 
network of mainly mitochondrial metabolic adaptations to changes of energetic 
homeostasis. (Scarpulla 2011) 
PGC-1α has been identified in the context of its role in adaptive thermogenesis in 
brown adipose tissue. (Puigserver et al. 1998) Subsequently, numerous additional 
processes have been found to be under the control of PGC-1α. Among these are 
metabolic responses to fasting, regulation of cellular respiration, glucose metabolism 
and energy homeostasis, regulation of mitochondrial generation of oxidants and 
antioxidant response, and mitochondrial biogenesis and turnover. PGC-1α has been 
studied extensively in brown adipose tissue, liver, skeletal muscle, heart, and brain. 
(St-Pierre et al. 2006, Tritos et al. 2003, Clark, Simon 2009, Esterbauer et al. 1999, 
Lin, Handschin & Spiegelman 2005, St-Pierre et al. 2003, Tsunemi, La Spada 2012) 
18 
 
All these tissues are highly dependent on oxidative metabolism and a closely 
regulated maintenance of energy supply. (Lin, Handschin & Spiegelman 2005) 
The variety of cellular processes that are regulated by or in some manner influenced 
via PGC-1α and downstream effectors points out the importance of this regulatory 
circuit and is as perplexing as the number of environmental cues that either have a 
direct impact on PGC-1α activity or indirectly trigger PGC-1α mediated responses. 
This points out the integrative function PGC-1α has within a nutrient sensing 
network maintaining energetic and oxidative balance, and coordinating the 
regulation of metabolic adaptation. (Lin, Handschin & Spiegelman 2005) 
PGC-1α is, first of all, expressed in a tissue specific manner. (Puigserver et al. 1998, 
Esterbauer et al. 1999) Furthermore, expression is regulated in response to 
environmental influences that restrict the availability of nutrients. As a consequence, 
intracellular cyclic adenosine monophosphate (cAMP) levels increase, and the 
transcription factor cAMP response element binding protein (CREB) is activated by 
protein kinase A (PKA). Together with other transcription factors, CREB induces 
expression of PGC-1α. (Lin, Handschin & Spiegelman 2005) 
PGC-1α is also directly activated in response to environmental stimuli and energetic 
alterations via posttranscriptional modifications. (Arduino et al. 2010, Scarpulla 
2011, Fernandez-Marcos, Auwerx 2011, Jeninga, Schoonjans & Auwerx 2010) 
Within this regulation network, the deacetlyase sirtuin (silent mating type 
information regulation 2 homolog) 1 (Sirt-1) functions as an immediate activator of 
PGC-1α activity. (Canto, Auwerx 2009) Sirt-1 belongs to a family of deacetlyases 
whose activity is dependent on intracellular NAD+ levels as well as NAD+/NADH 
and AMP/ATP ratios, reflecting the nutrient state of a cell. (Imai et al. 2000)  Energy 
deprivation increases Sirt-1 activity via a number of integrative signaling pathways. 
Sirt-1 decreases the acetylation levels of PGC-1α, which leads to an immediate 
activation of PGC-1α. PGC-1α is inactivated by acetylation via lysine 
acetyltransferase 2A (GCN5) under conditions of increased nutrient availability.   
(Nunnari, Suomalainen 2012, Fernandez-Marcos, Auwerx 2011, Jeninga, 
Schoonjans & Auwerx 2010) The regulatory network of PGC-1 activity in response 
to nutrient status is summarized in figure 3. 
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Figure 3 PGC-1 in the center of a mitochondrial nutrient sensing network. PGC-1α expression and activity are 
regualated via a network of mitochondrial sensors in dependence of the energetic status if the cell. Upon 
nutrient depletion, NAD+/NADH and AMP/ATP ratios rise, whereas acetyl-CoA concentrations decrease. This 
activates Sirt-1 and AMP (adenosine monophosphate)-activated kinase (AMPK), which leads to enhanced 
expression and activation of PGC-1. Deactivation of PGC-1 is mediated by lysine acetyltransferase 2A (GCN5) 
under conditions of high nutrient availability. NAD+/NADH: nicotinamide adenine dinucleotide, oxidized and 
reduced form, AMP: adenosine monophosphate, ATP: adenosine triphosphate. Reprinted by permission from 
Macmillan Publishers Ltd: Cell, (Nunnari, Suomalainen 2012) 
Apart from expression regulation, the specificity of PGC-1α targeting certain genes 
is partly conferred by interaction with transcription factors and their tissue specific 
expression patterns. As a coactivator of transcription, PGC-1α regulates and 
coordinates gene expression networks by interacting with a number of transcription 
factors, such as nuclear factors NRF-1 and NRF-2, and estrogen-related receptor 
ERR α. (Puigserver et al. 1998, Clark, Simon 2009, Wu et al. 1999, Mootha et al. 
2004, Scarpulla 2006)  
These transcription factors target a number of nuclear encoded mitochondrial genes: 
among the main expression networks under PGC-1α control are mitochondrial 
respiratory chain complexes and other enzymes involved in cellular respiration. (Lin, 
Handschin & Spiegelman 2005, Rohas et al. 2007) 
On a broader level, gene expression networks encoding for proteins promoting 
mitochondrial biogenesis depend on PGC-1α. Taken together, PGC-1α activation 
and increased expression of downstream networks results in an increased 
mitochondrial number per cell, as well as enhanced functional capacity of 
mitochondria. (Wareski et al. 2009) 
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Figure 4 PGC-1 in the center of regulatory networks translating environmental influences to transcriptional 
responses. PGC-1 expression is induced in response to environmental stimuli influencing energetic status, 
transduced by changes in cyclic AMP (cAMP) levels via protein kinase A (PKA) and the transcription factor CREB 
(cAMP response element-binding protein). PGC-1 in turn acts as coactivator of a number of transcription 
factors to enhance mitochondrial biogenesis and pathways involved in energy metabolism. NRF-1: nuclear 
factor 1, NRF-2: nuclear factor 2, ERR: estrogen-related receptor, PPAR: peroxisome proliferator-activated 
receptor . Reprinted by permission from Macmillan Publishers Ltd: Journal of Cellular Biochemistry,  (Scarpulla 
2006) 
Due to the higher mitochondrial respiration rate upon PGC-1 activation, the 
amounts of ROS generated as byproducts of oxidative phosphorylation also rise. 
Potentially harmful consequences of enhanced metabolic activity are as well 
counteracted via PGC-1α. In parallel with enhancing energy metabolism, PGC-1α 
stimulates the expression of mitochondrial antioxidants. This leads to a boost in the 
functional state of the oxidant scavenging system and retains the homeostasis. (St-
Pierre et al. 2006) This mechanism of immediate maintenance of low intracellular 
oxidant levels is essential for oxidative species management. PGC-1α regulated 
networks allow for increasing metabolic activity without consequential damage due 
to higher reactive oxygen levels. (St-Pierre et al. 2006, Zheng et al. 2010, Clark, 
Simon 2009, Lin, Handschin & Spiegelman 2005, St-Pierre et al. 2003, Kukidome et 
al. 2006, Valle et al. 2005) 
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1.3.2. PGC-1α in neuronal function  
While initially studied in brown adipose tissue, skeletal and heart muscle, and liver, 
the functional impact of PGC-1α on brain neurons has recently been coming into 
focus. All of the tissues critically dependent on PGC-1α functions are highly 
oxidative. In line with this, PGC-1α is an essential regulator of energy and oxidative 
stress homeostasis in neurons. (Wareski et al. 2009) PGC-1α expression is being 
increased in response to oxidative stress challenges and mediates the antioxidant 
system maintaining neuronal homeostasis. In contrast, cells lacking functional PGC-
1α are neither able to adequately react to oxidative stress nor to regulate energy 
homeostasis. (St-Pierre et al. 2006, Zheng et al. 2010, Lin et al. 2004) 
A number of studies have proven the essential function of PGC-1α in mitochondrial 
biogenesis and regulation, maintaining energy homeostasis and matching ATP 
production to the cellular need while also maintaining a low level of oxidative 
stressors in an integrative signaling network. PGC-1α has repeatedly been linked to 
neuroprotection and neurodegeneration. (St-Pierre et al. 2006, Zheng et al. 2010, 
Kelly, Scarpulla 2004, Puigserver, Spiegelman 2003, Lin et al. 2004, Scarpulla 2002, 
Mudo et al. 2012, Leone et al. 2005) 
In the following sections, I am going to review evidence for an essential function of 
PGC-1α in neurons, particularly with focus on the role of PGC-1α in 
neurodegenerative diseases and PD. 
 
1.3.3.  PGC-1α  in neuroprotection and neurodegeneration 
1.3.3.1. Clinical implications for a role of PGC-1α in Parkinson’s Disease 
Alterations in the expression of PGC-1α have been implicated as one of the 
underlying factors for neurodegenerative processes, and, in particular, PD 
pathogenesis. In a large meta-analysis of independent microarray based gene 
expression studies, Zheng and colleagues identified gene sets associated with PD.  
(Zheng et al, 2010)  
As a basis, Zheng and coworkers used gene expression studies on autopsy samples, 
including results based on analysis of different brain areas as well as selective 
studies of DA neurons. A number of gene set showing differential expression 
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patterns in PD patients with clinical as well as subclinical disease status as compared 
to healthy controls were identified. Underexpression of gene sets encoding biological 
functions was considered an indication for the respective pathways being affected 
during PD pathogenesis. Among the underexpressed gene sets, Zheng et al report a 
high prevalence of gene expression networks controlled by PGC-1α. Among the 
genes identified to be associated with PD, a substantial fraction was being 
contributed by molecular pathways involved in mitochondrial metabolism. Gene sets 
comprising the entire set of nuclear encoded electron transport chain subunits were 
found to be underexpressed in samples of subclinical as well as clinically prevalent 
PD. This holds true for DA neurons as well as non-nigral neurons. Other deregulated 
pathways that were identified by this study include several mitochondrial pathways 
involved in different stages of energy metabolism (predominantly glucose utilization 
based), and mitochondrial biogenesis and protein handling. 
A striking common feature of these pathways underexpressed in PD patients is their 
responsiveness to PGC-1α regulation. PGC-1α controlled networks were found to be 
defective and underexpressed in both substantia nigra as well as non-nigral tissues. 
The initial screening results were identified for these gene sets using quantitative 
real-time polymerase chain reaction (qPCR), and differential expression at low levels 
was detected association with in subclinical as well as clinical PD. 
Zheng and coworkers show that dysregulations in the gene expression levels of 
PGC-1α regulated networks, particularly those involved in mitochondrial energy 
metabolism and biogenesis, are strongly associated with PD and may be crucially 
contributing to disease development. (Zheng et al. 2010) 
Taking into consideration that PGC-1α is known to have a positive impact on the 
functional state of mitochondria, and to regulate energy homeostasis and metabolism 
in neurons, these clinical findings strongly suggest a crucial role of PGC-1α in 
neuroprotection against degenerative processes. (Wareski et al. 2009) 
 
1.3.3.2. Studies in model systems: Loss of PGC-1α   
Neuroprotective features of PGC-1α mediated gene expression networks have been 
studied in different model systems in vitro and in vivo. Studies of the effects of 
depletion of functional PGC-1α in cell culture as well as in mouse models have 
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helped identify downstream gene expression networks under the regulation of PGC-
1α. (St-Pierre et al. 2006, Wu et al. 1999, Rohas et al. 2007, Valle et al. 2005) 
Two independent reports characterizing stable PGC-1α null mouse lines have 
provided further evidence for the importance of PGC-1α in maintaining energetic 
and oxidative state homeostasis in brain neurons. Furthermore, these studies provide 
further evidence for dysregulations of PGC-1α mediated gene expression networks 
in neurodegenertion. (St-Pierre et al. 2006, Lin et al. 2004, Leone et al. 2005) 
Both of the PGC-1α depleted mouse models are based on whole body knockout of 
functional PGC-1α, resulting in a complete depletion of PGC-1α mRNA (messenger 
RNA, ribonucleic acid) and protein levels. PGC-1α knockout mice are viable, but 
suffer from abnormalities linked to disturbances in energy metabolism. Transgenic 
(tg) mice are unable to adapt their body temperature upon cold exposure, confirming 
the crucial involvement of PGC-1α in adaptive thermogenesis. (St-Pierre et al. 2006, 
Lin et al. 2004, Leone et al. 2005) 
Furthermore, mitochondrial oxidative phosphorylation is less efficient in liver and 
skeletal muscle of PGC-1α null mice. This suggests essential functions of PGC-1α 
and downstream metabolic networks in mitochondrial metabolism. (Leone et al. 
2005) 
Both PGC-1α null mouse lines showed structural abnormalities in the central 
nervous system. More specifically, lesions in several brain regions, including 
hippocampus (Hc) and cortex (Cx) were reported by both groups. St-Pierre et al also 
report lesions resembling neurodegenerative lesions in the striatum of tg mice. 
Additional neurodegenerative lesions were found in different brain areas. (St-Pierre 
et al. 2006, Lin et al. 2004, Leone et al. 2005) These findings are due to neuronal 
disruption of PGC-1α signaling, as proven by similar findings in mice with neuron-
specific knockout of PGC-1α, which develop comparable patterns of 
neurodegenerative lesions. (Ma et al. 2010) 
PGC-1α null mice exhibit pronounced changes in movement behavior, presumably 
due to disruption by the above described brain lesions. Signaling pathways are 
known to be disrupted in some of the brain regions affected in PGC-1α null mice 
also in human neurodegenerative diseases, predominantly in PD. This leads to the 
hypothesis that PGC-1α obtains an essential function in neuroprotection and 
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disruption of PGC-1α mediated signaling pathways is a crucial feature of 
neurodegeneration. (St-Pierre et al. 2006, Lin et al. 2004, Leone et al. 2005) 
Further characterization of the neurodegenerative lesions and consequences for 
functional state and health of PGC-1α null mice central nervous system was 
performed with the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridin (MPTP) mouse 
model of PD. (St-Pierre et al. 2006) MPTP is a precursor form of the neurotoxin 1-
methyl-4-phenylpyridinium (MPP+). MPTP is metabolized to its active form in glial 
cells and partly in neurons, and MPP+ is selectively taken up by the dopamine 
transporter into DA neurons, where it inhibits complex I of the mitochondrial 
respiratory chain. This causes an increase in the amount of ROS that is produced 
during the cellular respiration. (Przedborski et al. 2004) 
MPTP is widely used as a model for neurodegenerative processes similar to those 
seen in PD. Reviewed in (Winklhofer, Haass 2010) In wildtype (wt) as well as PGC-
1α null mice, MPTP causes a reduction in the number of DA neurons in parallel with 
an increase in oxidative stress levels. MPTP induced neurodegeneration is associated 
with increased levels of oxidative damage, predominantly in substantia nigra. PGC-
1α knockout mice show more pronounced loss of TH-positive DA neurons in the 
substantia nigra than controls. (St-Pierre et al. 2006) 
Excitotoxicity in the context of PGC-1α depletion has also studied in PGC-1α null 
mice. Kainic acid is used as a model for oxidative stress via excitotoxic mechanisms, 
and known to confer excitotoxic damage to hippocampal neurons via an increase of 
oxidative stress. The increased vulnerability of brain neurons lacking PGC-1α also 
holds true under excitotoxic conditions: PGC-1α null mice are more susceptible 
towards excitotoxic stress than wt controls. (Wang et al. 2005) 
The higher vulnerability of PGC-1α depleted neurons towards excitotoxic and 
oxidative stress assaults shows an essential role of PGC-1α in neuroprotection 
against similar processes. Further characterization of neurons under PGC-1α 
depletion using gene expression analysis revealed underexpression of genes linked to 
mitochondrial oxidative phosphorylation. In line with this, skeletal muscle cells of 
PGC-1α null mice show reduced expression levels of a number of genes involved in 
mitochondrial electron transport chain, ATP production and energy metabolism. In 
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addition, expression of mitochondrial antioxidants was shown to be decreased in the 
brains of PGC-1α null mice. (St-Pierre et al. 2006) 
 
1.3.3.2. Studies in model systems: Gain of PGC-1α  
The fact that loss of PGC-1α is clinically correlated with neurodegeneration as well 
as the findings provided by studies in PGC-1α null mice point towards a strong role 
of PGC-1α in neuroprotection. In order to study the effects of increased PGC-1α 
levels in neurons, my colleagues have established a mouse line with stable 
overexpression of PGC-1α in brain neurons (Mudo et al. 2012). 
The PGC-1α tg mouse line expresses flag-tagged exogenous PGC-1α under the 
control of the neuron-specific Thy1.2 promoter. This renders the expression of 
exogenous PGC-1α specific to brain neurons. The Thy1.2 promoter is activated after 
birth, and remains driving expression of PGC-1α from then on. (Vidal et al. 1990, 
Caroni 1997) Expression of exogenous PGC-1α results in increased protein levels in 
different brain areas of the tg mice, as reported for substantia nigra, pars compacta 
(SNc) and striatum. (Mudo et al. 2012) 
In order to study possible neuroprotective properties conferred by PGC-1α 
overexpression, tg mice were treated with the neurotoxin MPTP. As reviewed in 
chapter 1.3.3.2., MPTP causes oxidative stress in DA neurons by means of inhibition 
of complex I of the mitochondrial respiratory chain. This allows studying 
disturbances in cellular physiology similar to those in neurons under 
neurodegenerative assaults in PD. 
Unlike wt control mice, where MPTP causes a pronounced decrease in the number of 
TH positive DA neurons in the substantia nigra, PGC-1α tg mice are almost 
completely resistant towards this oxidative stressor. Upon MPTP treatment, the 
number of viable TH-positive DA neurons does not undergo significant changes in 
PGC-1α tg mice, and equally, the overall number of neurons remains stable upon 
MPTP treatment. In addition, the functional state of the nigrostriatal system was 
found to be enhanced in PGC-1α tg mice, measured as improved dopamine 
metabolism. 
This shows that PGC-1α overexpression renders DA neurons of the nigrostriatal 
system less susceptible towards oxidative assaults. Together with the findings of an 
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increased vulnerability of PGC-1α null mice towards MPTP mediated 
neurodegeneration, the strong neuroprotective function of PGC-1α overexpression 
indicates an essential role of endogenous PGC-1α expression and signaling in 
neuroprotection.  
In order to study the mechanisms underlying the neuroprotection mediated by PGC-
1α, gene expression in brains of PGC-1α tg mice was assessed. The mitochondrial 
antioxidants superoxide dismutase 2 (SOD2) and thioredoxin 2 (Trx2) are present at 
higher levels in the SNc of tg mice. This enhanced expression is accompanied by a 
rise in mRNA for SOD2. 
Furthermore, the respiratory control ratio was found to be enhanced in mitochondria 
purified from whole brain extracts of PGC-1α tg mice, as compared to wt controls, 
showing an improved capacity for ATP production and mitochondrial energy 
metabolism in neurons of PGC-1α tg mice. In line with this, expression levels of 
mRNA encoding the subunit IV of mitochondrial eletron transport chain complex IV 
were found to be increased in substantia nigra of tg mice. This change in 
transcriptional activity was also reflected by increased protein levels. 
These results show that PGC-1α overexpression causes functional alterations in the 
expression of mitochondrial genes involved in energy metabolism and oxidative 
stress scavenging pathways. These changes lead to an enhanced response to 
oxidative stress, which may increase the capability of DA neurons to scavenge 
oxidative assaults and thereby contribute to enhancing cell viability under oxidative 
conditions. PGC-1α overexpression enhances the functional state of mitochondrial 
energy production and improves the neurons’ ability to maintain energy homeostasis. 
Taken together, the findings reported by Mudò et al strongly suggest a role of PGC-
1α in contributing to the control of oxidative stress response and a neuroprotective 
role of PGC-1α against processes as observed in PD. (Mudo et al. 2012) 
 
1. 4. GABAergic signaling and implications of PGC-1 
-aminobutyric acid (GABA) is one of the main inhibitory neurotransmitters in the 
brain, with most of the fast synaptic inhibitory signaling being mediated by GABAA 
receptors. GABAA receptors are ionotropic receptor channels with selectivity for 
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anions. In brain neurons, GABA-mediated opening mostly allows an influx of 
chloride, which stabilizes the membrane potential close to the resting potential. This 
decreases the probability of depolarization, and has a physiological role 
predominantly in inhibitory postsynaptic signaling.   
GABAA receptors are pentameric receptors composed of different combinations of α, 
β, and γ subunits. Subunit composition varies depending on the function and location 
of the receptors and influences the functional properties of the receptors. 
GABAA receptors mediate mainly synaptic, phasic and fast inhibition. In addition, 
however, they also contribute to extrasynaptic, tonic inhibitory signaling. The 
location and functionality of a receptor is determined by its subunit composition and 
depends on neuronal activity. (Hines et al. 2012, Holopainen, Lauren 2003, Purves 
2012) 
Alterations in GABAA receptor subunit composition have been reported in context of 
neuronal demise, and GABAergic signaling has been associated with protective 
properties against excitotoxicity. Particularly, enhanced GABA mediated inhibition 
can protect neurons from excitotoxic cell death, as studied after stroke. (Hines et al. 
2012) 
Localization of PGC-1α to GABAergic neurons and regulatory networks have been 
studied in rat brains. During development of the rat brain, most GABAergic neurons 
were found to express PGC-1α. Equally, in mature rat brains, PGC-1α was found to 
be strongly expressed in hippocampal and cortical GABAergic neurons. (Cowell, 
Blake & Russell 2007) 
Functional properties of inhibitory interneurons in hippocampus, cortex, and striatum 
of PGC-1α depleted mice undergo changes, due to alterations in expression patterns 
of proteins involved in calcium-signaling. It is thought that these changes have an 
impact on GABA release and may impair inhibitory signaling properties. It has been 
suggested that PGC-1α depletion is associated with interneuron pathology in 
neurodegeneration. (Lucas et al. 2010) 
Furthermore, studies in PGC-1α knockout mice suggest that PGC-1α expression in 
GABAergic neurons has an essential function role in neuronal protection from 
excitotoxicity, possibly due to maintenance of energetic homeostasis and 
neuroprotection via antioxidants. (Cowell, Blake & Russell 2007, Lucas et al. 2010) 
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1.5. Quantitative real-time PCR 
Quantitative real-time PCR (qPCR) is based on the exponential amplification of a 
DNA template during PCR reaction. By thermal cycling, DNA template 
conformation is repeatedly altered from single- to double stranded, and, during 
amplification reactions characterized by ideal temperature conditions for firstly, 
primer annealing to a target sequence within the DNA template and, secondly, 
amplification of this sequence by a heat-stable DNA polymerase. The newly 
synthesized double stranded products are separated by a steep increase in 
temperature and can subsequently serve as templates during the next amplification 
cycle. In order to render the amount of double stranded PCR product measurable, a 
fluorescent dye, in this Master’s thesis study SYBR Green, is added to the initial 
reaction. SYBR Green intercalates unspecifically in double stranded DNA. Binding 
to DNA causes SYBR Green to undergo a conformational change, which in turn 
leads to a pronounced increase in fluorescence emission. In consequence, 
fluorescence levels directly reflect the amount of double stranded DNA. Reviewed in 
(VanGuilder, Vrana & Freeman 2008) 
In a qPCR setup, this principle is utilized by measuring the fluorescence intensity 
repeatedly throughout the reaction and thereby monitoring the amplification of 
template. Amplification specificity for a targeted gene is conferred by specific 
primers. During the amplification reaction, the amount of PCR-product increases 
exponentially, with (under ideal conditions) a doubling of reaction product during 
each cycle. By following the fluorescence increase during the PCR reaction, the 
quantification cycle (Cp) value can be determined. The Cp value is defined as the 
number of amplification cycles that is needed until the fluorescence intensity crosses 
a preset threshold value and is clearly discernible from background fluorescence. 
(Schmittgen, Livak 2008) It thus is indirectly correlated with the initial template 
copy number in the starting reaction, as it reflects the presence of a sufficient copy 
number of product for fluorescence to cross the threshold.  The number of 
amplification cycles required until the Cp value is reached allows conclusions about 
the initial amount of a template (determined by the primer sequence specificity) in 
the starting reaction. Comparing Cp values for the same template for reactions 
containing complementary DNA (cDNA) of different samples allows for calculating 
the relative amounts of template present in the initial reactions. This approach is 
29 
 
widely used to measure relative gene expression levels of target genes. A well-
established method, used in this Master’s Thesis study, is the ΔΔCp method for 
relative quantification. (Schmittgen, Livak 2008, Pfaffl 2001, Livak, Schmittgen 
2001)  
This method is based on reverse transcription of mRNA to cDNA, with the mRNA 
directly reflecting the transcriptional activity upon target genes. During reverse 
transcription, the relative abundances of transcripts for individual genes are 
maintained. The cDNA population that is used as input for qPCR therefore reflects 
the mRNA population and expression levels. Reviewed in (Dorak 2006) 
Figure 5 shows a representative amplification course for qPCR reactions. In the 
example, the expression level of a target gene is to be compared between tg and 
control samples. Amplification of the target gene specific transcript yields Cp values 
for both samples.  To render the obtained Cp values comparable, expression is, in a 
first step, normalized to one or several reference genes. These are genes known to be 
expressed at stable levels among varying conditions and not being influenced by 
changes in the expression of other genes. Commonly, gene expression levels of 
genes of interest are given as a relative value in dependence on the expression of 
reference genes.  (Pfaffl 2001, Dorak 2006) 
In a qPCR setup, amplification reactions for the reference genes are performed in 
parallel to the reactions for the target genes. Cp values of reference genes in tg and 
control sample are subtracted from the corresponding Cp values for the target genes. 
This normalization yields the ΔCp value for both the tg and the control sample 
(compare figure 5). ΔCp, or the expression differences between target and reference 
gene, is a relative value for the level of gene expression of the target gene, as 
compared to the stable expression level of a reference gene. (Pfaffl 2001, Dorak 
2006) 
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Figure 5 Principle of relative gene expression measurement with the  ΔΔCp method for relative 
quantification. Adapted from (Dorak 2006) 
The difference between the ΔCp values for transgenic and control samples reflects the 
difference in expression levels between the samples. Under ideal reaction conditions, 
the relative expression ratio (R) is given as follows (Livak, Schmittgen 2001): 
                                        
In order to ensure reliability, the calculation is adapted to take into account 
differences between the reaction efficiencies for different genes. Calculation of 
relative gene expression of a target gene in the transgenic sample, normalized to the 
expression of a reference gene, is then summarized in the following formula, 
adapted from (Dorak 2006): 
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E describes the efficiency value (calculation of efficiencies is described in chapter 
4.1.2.), which is a measure for the dynamic development of the amplification 
reaction. Under optimal reaction conditions, the efficiency of a qPCR reaction equals 
2.0, which corresponds to a perfect doubling of input DNA template during each 
amplification cycle. (Pfaffl 2001, Dorak 2006) 
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2. Aims of the study 
This Master’s Thesis study is based on the transgenic mouse line established by 
Mudò et al. (Mudo et al. 2012) Aims of this study were to further characterize the 
transgenic mouse line in order to identify functional alterations and gene expression 
networks associated with overexpression of PGC-1α.  
Previously, a microarray based screening was performed, and revealed differential 
gene expression in hippocampus and cortex of PGC-1α transgenic mice. From the 
differentially regulated genes, a subset of genes was chosen for further study. These 
included genes encoding mitochondrial proteins known to be part of metabolic and 
regulatory pathways with established links to PD pathogenesis. 
For this, I established a qPCR based system for reassessment of differential gene 
expression in wildtype and PGC-1α transgenic mouse brains. Immunohistochemistry 
supplemented the analysis with expression studies at the protein level. 
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3. Materials and methods 
3.1. Workflow of the analysis 
Transgenic mice of the PGC-1α overexpressing strain created and described by 
Mudò et al were in the focus of this Master’s Thesis study. C57BL/6J mice (The 
Jackson Laboratory, Bar Harbor, ME, USA) were chosen as wt controls in 
accordance with the genetic background of the tg mice. (Mudo et al. 2012) 
Mice of the tg strain express flag-tagged PGC-1α under the control of the neuron-
specific Thy1.2 promoter. (Vidal et al. 1990, Caroni 1997) Tg mice were genotyped 
at an age of approximately three weeks.  
For analysis of the gene expression levels, eight week old male mice were sacrificed 
and tissues (Hc and Cx) were excised. RNA extraction was performed with the 
RNeasy Lipid Tissue Mini Kit (QIAGEN, Hilden, Germany). This method is based 
on a phenol chloroform extraction followed by column based purification of RNA. 
After quantification of the yield and quality control, RNA was used for cDNA 
synthesis using SuperScript VILO cDNA Synthesis Kit (Invitrogen, Carlsbad, CA, 
USA).  
cDNA was used for quantitative real time PCR on a Roche LightCycler 480 II 
(Roche Diagnostics, Basel, Switzerland) with the SybrGreen method of 
quantification. qPCR was performed to study the expression levels of 14 genes of 
interest, chosen based on the results of a microarray (GeneChip Mouse Exon ST 
Array, Affymetrix, Santa Clara, CA, USA), performed earlier in our research group. 
 
3.2. Genotyping 
Tg mice were genotyped for expression of exogenous PGC-1α at an age of three 
weeks using ear tissue samples. For tissue lysis, samples were incubated at 96ºC in 
75µl of buffer containing 25mM NaOH and 0.2mM EDTA for 45 minutes (min) and 
briefly cooled on ice. The reaction was stopped by adding 75µl of a 40mM Tris-
solution (pH 8).  
Genotyping was performed with a PCR assay targeting the exogenous PGC-1α gene. 
Per single reaction, 5µl of DNA-extract was added to a Master Mix consisting of 5µl 
F-518 5x Phusion HF Reaction Buffer (Thermo Scientific, Waltham, MA, USA), 
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0.5μl dNTP mix (10mM, Thermo Scientific, Waltham, MA, USA), 1µl each sense 
(S) and antisense (AS) primer (20µM), 0.2µl F-530S Phusion DNA Polymerase 
2U/µl (Thermo Scientific, Waltham, MA, USA) and 12.3µl dH2O (distilled H2O, 
BPC grade, Sigma Aldrich, Saint Louis, MO, USA)  to a final volume of 25µl. 
PCR for expression of exogenous PGC-1α was performed using the following primer 
sequences:  
S 5’-CACTTCCTTGGCTTTCTCT-3’, AS 5’-GTATCCAAGTCATTCACAT-3’ 
(Thermo Scientific, Waltham, MA, USA). 
The PCR reactions were incubated in Low Tube Strip Individual PCR Tubes
 
(BioRad, Hercules, CA, USA) in a BioRad C1000 Thermal Cycler (BioRad, 
Hercules, CA, USA) under the following conditions:  
  
Temperature 
(ºC) 
Time  
Denaturation  94 5min  
Amplification 
Denaturation 94 60s 
36 cycles Annealing 55 60s 
Extension 72 60s 
  72 10min  
Table 1 PCR reaction conditions for genotyping.  
PCR products were mixed with 6x DNA loading dye (Thermo Scientific, Waltham, 
MA, USA) and run on a 1% agarose gel (SeaKem LE  agarose, Lonza, Basel, 
Switzerland) in 0.5x TBE buffer (44.5mM Tris, 44.5mM boric acid, 1.0mM EDTA, 
pH 8.0) containing SYBR Safe DNA gel stain (Invitrogen, Carlsbad, CA, USA ) in a 
1:10,000 dilution for visualization of DNA under UV light. 10μl DNA size standard 
(Quick-Load 100bp DNA Ladder or Quick-Load 100bp plus DNA Ladder, New 
England Biolabs, Ipswich, MA, USA) were loaded. Gels were run in 0.5x TBE 
buffer at 100V for 40-45 min on a PowerPac basic (BioRad, Hercules, CA, USA. 
PCR products resulted in bands of a lengths of 420bp, which were visualized under 
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UV light in an AlphaImager gel documentation system using AlphaImager Mini 
software (Protein Simple, Santa Clara, CA, USA). 
 
3.3. RNA extraction 
PGC-1α tg mice and wt controls were sacrificed at an age of eight weeks. 
Hippocampi and a tissue sample of the cortex were excised, taken up in ice cold 
RNAlater RNA Stabilization Reagent (QIAGEN AB, Hilden, Germany) and kept on 
ice to prevent degradation until RNA extraction was performed. The weight of the 
excised tissues ranged from 10 to 30mg. 
RNA extraction was performed with the QIAGEN RNeasy Lipid Tissue Mini Kit 
(QIAGEN AB, Hilden, Germany) according to manufacturer’s instructions. The 
workflow is based on a phenol-chloroform extraction of total RNA followed by 
silica-membrane based purification. 
After transfer to reaction tubes containing ceramic beads (Precellys 24 Lysing Kit 
soft tissue homogenizing CK14, 1.4mm ceramic zirconium oxide beads in 0,5mL or 
2mL standard tubes, Bertin Technologies, Aix-en-Provence, France), tissue samples 
were homogenized in 500µl or 1000µl QIAzol Lysis Reagent (QIAGEN AB, Hilden, 
Germany). Tissues were homogenized by operating the samples at 6,500rpm for 45s 
twice with 15s intermediate break in a Precellys 24 tissue homogenizer (Bertin 
Technologies, Aix-en-Provence, France). 
The homogenization step disrupts cellular membranes, promoting release of contents 
of the cytosol and cellular organelles into solution, and causes shearing of large 
molecules. QIAzol Lysis Reagent consists of phenol and guanidine thiocyanate. 
Guanidine thiocyanate is a chaotropic agent denaturating macromolecules. In 
addition, RNAses are inactivated. This contributes to protection of RNA from 
degradation. This lysis reagent is particularly suitable for extraction of nucleic acids 
from tissues with high fat contents, such as brain. 
Homogenates were transferred to microreaction tubes and incubated at room 
temperature for 5min to facilitate access to nucleic acids by allowing dissociation of 
nucleoprotein complexes. 
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After formation of an emulsion with chloroform (Sigma-Aldrich, Saint Louis, MO, 
USA), samples were separated into three phases by a prolonged centrifugation step. 
During this process, RNA partitions to the upper, aqueous phase, which then was 
separated and used for further purification steps. In addition, the sample contains an 
intermediate phase in which DNA is concentrated, and an organic phase containing 
proteins and lipids.  
The aqueous phase containing RNA was extracted and mixed with an equal amount 
(600µl, typically) of 70% ethanol in order to provide appropriate binding conditions 
for the following column purification steps. Spin columns provided with the kit 
contain a silica membrane to which all RNA molecules with a length of more than 
200 bases are adsorbed. This enriches the sample for mRNA, since shorter RNAs are 
removed during purification. RNA remains attached during the subsequent washing 
steps using buffers provided with the kit, whereas purification reagents and 
contaminants are removed. RNA was eluted in 50µl RNAse-free water and stored at 
-70°C for further use. 
RNA yield after purification was quantified photospectrometrically using a NanoVue 
plus spectrophotometer (GE Healthcare, Chalfont St Giles, Switzerland). Purity of 
RNA was assessed in dependence of the A260/A280 ratio, which allows ruling out 
protein contaminations in the sample. 
 
3.4. cDNA synthesis 
First-strand DNA for qPCR reactions was synthesized from the extracted RNA using 
the SuperScript VILO cDNA Synthesis Kit (Invitrogen, Carlsbad, CA, USA). 
In a reverse transcription reaction, the RNA population was converted to cDNA 
subsequently serving as a starting template for qPCR reactions. 
The SuperScript VILO cDNA Synthesis Kit contains a modified murine leukemia 
virus (M-MLV) reverse transcriptase. The reverse transcription reaction is dependent 
on binding of random primers to the purified RNA. Thereby, RNA obtained from the 
samples is transcribed to cDNA without affecting the ratios of RNAs in the sample. 
The cDNA used as input for qPCR thus reliably reflects the mRNA population as an 
average of the transcriptional activity in the sample cells.  
37 
 
As input for a 20μl reaction, 2.5μg RNA was used. For negative controls, RNA input 
was replaced with dH2O (H2O, BPC grade, Sigma Aldrich, Saint Louis, MO, USA). 
cDNA synthesis reactions were  incubated in a BioRad C1000 Thermal Cycler 
(BioRad,  Hercules, CA, USA) according to instructions provided with the kit, as 
summarized in the following table: 
 
 
 
 
cDNA was stored at -20°C until further use. Effective cDNA synthesis was assessed 
by performing PCR for actin β. cDNA diluted 1:10 in dH2O (H2O, BPC grade, 
Sigma Aldrich, Saint Louis, MO, USA) was used as input for the PCR reaction. Per 
single reaction, 2.5μl of diluted cDNA were added to 22.5μl Master Mix containing 
5µl F-518 5x Phusion HF Reaction Buffer (Thermo Scientific, Waltham, MA, USA), 
0.5μl deoxynucleotide (dNTP) mix (10mM each, Thermo Scientific, Waltham, MA, 
USA), 1µl each S and AS primer (20µM), 0.2µl F-530S Phusion DNA Polymerase 
2U/µl (Thermo Scientific, Waltham, MA, USA) and 14.8µl dH2O (H2O, BPC grade, 
Sigma Aldrich, Saint Louis, MO, USA)  to a final volume of 25µl. Negative controls 
containing undiluted cDNA negative control reactions instead of cDNA were run for 
every assay. 
Primer sequences were: S 5’ – CAC ACT GTG CCC ATC TAT GA – 3’, AS 5’ – 
CCA TCT CTT GCT CGA AGT CT – 3’ (Sigma-Aldrich, Saint Louis, MO, USA). 
PCR reactions were incubated in Thermo Scientific ABgene 0.5mL PCR Tubes 
(Thermo Scientific, Waltham, MA, USA) under the following conditions in a 
BioRad C1000
 
Thermal Cycler (BioRad, Hercules, CA, USA): 
 
 
Temperature 
(ºC) 
Time (min) 
Pre-incubation 25 10 
cDNA synthesis 42 60 
Termination of reaction 85 5 
Table 2 Reaction 
conditions for cDNA 
synthesis. 
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  Temperature 
(ºC) 
Time  
Denaturation  95 10min  
Amplification Denaturation 95 30s 31 cycles 
Annealing 60 30s 
Extension 72 30s 
Reaction 
termination  
 72 10min  
Table 3 PCR reaction conditions for detection of actin β. 
Under addition of 6x DNA loading dye (Thermo Scientific, Waltham, MA, USA), 
PCR products were loaded on a 1% agarose gel (SeaKem LE  agarose, Lonza, Basel, 
Switzerland, in 0.5x TBE buffer) containing SYBR Safe DNA gel stain (Invitrogen, 
Carlsbad, CA, USA ) and gels were run in 0.5x TBE buffer at 100V for 40-45 min 
on a PowerPac Basic (BioRad, Hercules, CA, USA). Size standards were Quick-
Load 100bp DNA Ladder or Quick-Load 100bp plus DNA Ladder (New England 
Biolabs, Ipswich, MA, USA), of which 10μl were loaded. PCR products were 
visualized under UV light in an AlphaImager gel documentation system using 
AlphaImager Mini software (Protein Simple, Santa Clara, CA, USA) as bands of 
approximately 200bp. 
 
3.5. Quantitative real-time PCR 
SYBR Green I-based quantitative real-time PCR (qPCR) was performed on a Light 
Cycler 480 II Real-Time PCR System (Roche Diagnostics, Basel, Switzerland). 
Reactions were run in 96 well plate format (LightCycler 480 Multiwell Plate 96, 
white; 5x10 plates with sealing foils, Roche, Basel, Switzerland) with a final volume 
of 10µl per reaction. 
All primers were obtained from Sigma-Aldrich (Saint Louis, MO, USA). 
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Actin β and GAPDH were used as reference genes. Primer sequences were: Actin β, 
S 5’-CCTTCTTGGGTATGGAATC-3’, AS 5’- TGTTGGCATAGAGGTCTT-3’, 
and GAPDH S 5’-CGACTTCAACAGCAACTC-3’, AS 5’-
TATTCATTGTCATACCAGGAA-3’. 
Genes of interest were targeted using the following primer sequences: 
Gene   Primer sequence (5’- 3’) 
Citrate lyase Acly S TGAATACCGAGGACATTA 
 AS ATTGAATAGACCAGAGATG 
Autophagocytosis associated   
protein 3 
Atg3 S AGATGGAGTATTCGGATGA 
 AS CCTGTAATACCTGTGTTGT 
ATP synthase, H+ transporting, 
mitochondrial F0 complex, 
subunit d 
Atp5h S AGAAGGAGGATGTGAAGA 
 AS TCAAGTCATCAATGGTCAT 
Cytochrome c oxidase,           
subunit Vb 
Cox5b S AAGGGACTGGACCCATAC 
 AS CACTATTCTCTTGTTGCTGATG 
Cytochrome c oxidase,               
subunit VIIb 
Cox7b S CGTGGTTATATTTGGAAT 
 AS GATTAAGGATTATGCTGAA 
GABA receptor subunit 2 Gabra2 S AACTAGACTTGGTTACTTT 
 AS TCTACTGTAAGCTCTACC 
GABA receptor subunit 2  Gabrg2 S AATCCGTGGTTATTGTAA 
 AS GTATCTTGCTCAGTGTAA 
Glutathione reductase Gsr S GCATGATAAGGTACTGAG 
 AS TACTTCCTTAACCTGTGT 
NADH dehydrogenase 1, 
subcomplex 13 
Ndufa13 S CATGTGCCCACTCCCAAG 
 AS AGTCACTTCACAAGGCAGAAA 
Neural precursor cell expressed, 
developmentally                       
down-regulated 8 
Nedd8 S AGTGAAGAAACTTGGTTC 
 AS AGTAGACACACAAGATTG 
Peroxisome proliferator-
activated receptor gamma, 
coactivator 1 
PGC-1α S CAAACCAACAACTTTATC 
 AS TAGTCTTGTTCTCAAATG 
Ras homolog enriched in brain Rheb S GTTCCCTGGTTCTATTAAC 
 AS AACACGGAAGATAGAGAC 
Sirtuin 1 (silent mating type 
information regulation 2, 
homolog) 
Sirt-1 S ATTGAAGATGCTGTGAAGTTAC
TG 
 AS GGAGACAGAAACCCCAGC 
Ubiquitin-like modifier 
activating enzyme 3 
Uba3 S TCACTCCAGTTCTTGTTAG 
 AS AACCAGATAATGCCAGATT 
Table 4 Primer sequences for gene expression measurement using qPCR. S: sense primer, AS: antisense primer 
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Reaction conditions were optimized for each target gene to ensure most suitable 
reaction conditions and accuracy of quantification. As a first step, reaction 
conditions and primer concentrations were modified, if necessary, to obtain 
maximum specificity and sensitivity for individual primer pairs. This was followed 
by assessment of the reaction efficiencies for each gene. For the subsequent 
calculation of gene expression levels, amplification efficiencies were used as a 
parameter for the reaction rate of the PCR reaction. For a more detailed description 
of the optimization process, see chapter 4.1. 
Measurements of gene expression levels were performed in reactions with a final 
volume of 10µl containing 5µl LightCycler 480 SYBR Green I Master (Roche, 
Basel, Switzerland), 2µl LightCycler 480 SYBR Green Master H2O (Roche, Basel, 
Switzerland), 1µl primer mix, and 2µl cDNA, diluted 1:100 in dH2O (H2O, BPC 
grade, Sigma Aldrich, Saint Louis, MO, USA). Final cDNA dilution therefore was 
1:500. Reactions were run in triplets, and no template controls (NTC), in which 
cDNA was replaced by LightCycler 480 SYBR Green Master H2O (Roche, Basel, 
Switzerland), were included for each gene. 
Expression levels in Hc and Cx of PGC-1 tg mice were determined in unpaired 
measurements in comparison to three wt controls for each of the genes of interest. 
All samples per target gene were measured within the same run to ensure 
comparable conditions for measurement. For each of the tg mice, measurements 
were repeated three to six times per tissue and gene of interest. In-run quality control 
was based on deviations of Cp values and analysis of melting temperature and 
dissociation curves. Biological replicates were measured within one run. Influence of 
sample position on the plate was assessed and position effects were excluded to 
ensure comparability between different runs.  
Expression level calculations were performed based on the ΔΔCp method (as 
reviewed in chapter 1.5.). Gene expression values were normalized against the 
average of reference genes actin β and GAPDH. LightCycler analysis software 
(Roche Diagnostics, Basel, Switzerland) was used for calculations. For statistical 
analysis of significance levels, Student’s T-test for paired measurements was 
performed. Significance levels for expression changes were assessed with one- and 
two-tailed T-test. P-values for directional changes in expression are given as 
calculated by one-tailed T-test. 
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Reaction conditions have been chosen based on prior optimization steps to ensure the 
highest possible specificity and sensitivity for each target gene. Reaction conditions 
for each of the reference and target genes are summarized in table 5, and qPCR 
programs used for final measurement can be found in table 6. 
 
Gene 
cDNA dilution 
(final) 
Primer 
concentration S 
(final) 
Primer 
concentration AS 
(final) 
Program 
1 Actin β 1:500 0,5μM 0,5μM + 
  
1:500 0,5μM 0,5μM – 
2 Gapdh 1:500 0,5μM 0,5μM + 
  
1:500 0,5μM 0,5μM – 
3 Acly 1:500 0,5μM 0,5μM + 
4 Atp5h 1:500 0,5μM 0,5μM + 
5 Atg3 1:500 0,4μM 0,2μM – 
6 Cox5b 1:500 0,2μM 0,4μM – 
7 Cox7b 1:500 0,5μM 0,5μM 
+   
5 additional  
cycles 
8 Gabra2 1:500 0,5μM 0,5μM + 
9 Gabrg2 1:500 0,5μM 0,5μM + 
10 Gsr 1:500 0,5μM 0,5μM + 
11 Ndufa13 1:500 0,4μM 0,4μM – 
12 Nedd8 1:500 0,5μM 0,5μM + 
13 PGC-1 1:500 1μM 1μM – 
14 Rheb 1:500 0,5μM 0,5μM + 
15 Sirt-1 1:500 0,5μM 0,5μM + 
16 Uba3 1:500 0,5μM 0,5μM + 
Table 5 Reaction conditions for gene expression measurement using qPCR S: sense primer, AS: antisense 
primer. + qPCR program run including extension time during the amplification step, - qPCR program run without 
extension time. 
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A. qPCR program run with extension time (+) 
  Temperature 
(ºC) 
Time   
Denaturation  95 15min   
Amplification Denaturation 95 15s  45 
cycles 
Annealing 60 20s  
Extension 72 10s Acquisition 
at end 
Melting 
curve 
analysis 
 65 1min Continuous 
acquisition 
 
 95 Continuous Continuous 
acquisition 
 
 37 1s   
B. qPCR program run without extension time (–)  
  Temperature 
(ºC) 
Time   
Denaturation  95 15min   
Amplification Denaturation 95 15s  45 
cycles 
Annealing 60 20s Acquisition 
at end 
Melting 
curve 
analysis 
 65 1min Continuous 
acquisition 
 
 95 Continuous Continuous 
acquisition 
 
 37 1s   
Table 6 Thermal conditions for qPCR reactions. A. program run with extension time during the amplification 
step. B. program run under removal of extension time. 
 
3.6. qPCR optimization 
During the optimization of the qPCR setup, resulting in the final measurement 
conditions shown above, reaction conditions were modified repeatedly. This 
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concerns both reaction temperatures and times in qPCR programs as well as primer 
conditions.  
In chapter 4.1., representative steps of the optimization process are presented for 
some of the genes of interest. For the purpose of qualitative analysis of PCR 
products, PCR was run on a BioRad C1000 Thermal Cycler (BioRad, Hercules, CA, 
USA). Except for modifications of primer concentrations, reagents and their 
concentrations were similar to the ones given above for qPCR. Conditions were as 
summarized in table 7. The conditions were kept similar to the amplification 
program of the qPCR conditions for expression analysis, as shown below. 
  Temperature 
(ºC) 
Time  
Denaturation  95 15min  
Amplification Denaturation 95 15s 35 - 40 
cycles 
Annealing 60 20s 
Extension 72 10s 
Table 7 Thermal conditions for PCR reactions for qualitative analysis of products under qPCR conditions. 
Modification to this basic program needed for optimization are stated explicitly 
together with the respective results in chapter 4.1. 
Amplification products of qualitative PCR and qPCR were run on 1% or 2% agarose 
gels in 0.5x TBE buffer (44.5mM Tris, 44.5mM Boric acid, 1.0mM EDTA, pH 8.0) 
containing SYBR Safe DNA gel stain (Invitrogen, Carlsbad, CA, USA) in 1:5,000 to 
1:10,000 dilution. 
 Reaction products were diluted adequately for optimal visualization in dependence 
on the gene expression levels, and 6x DNA loading dye (Thermo Scientific, 
Waltham, MA, USA) was added prior to loading. 10μl of size standards (Quick-
Load 50bp DNA Ladder or Quick-Load 100bp Ladder, New England Biolabs, 
Ipswich, MA, USA) were loaded in parallel. Gels were run at 60V for 60-120min 
and bands were visualized under UV light in an AlphaImager gel documentation 
system with AlphaImager Mini software (Protein Simple, Santa Clara, CA, USA). 
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3.7. Immunohistochemistry 
Brains of 6 month-old wt and tg mice embedded in paraffin were prepared for 
immunohistochemistry (IHC). 5μm thick coronal sections were obtained (Microm 
HM240E, Thermo Scientific, Waltham, MA, USA), collected on microscope slides 
(Thermo Scientific, Waltham, MA, USA) and dried at 37°C over night. 
Hippocampal sections were collected from Bregma -4.30 to -6.50. 
Sections were stained for endogenous PGC-1α, exogenous PGC-1α (represented by 
staining for flag-tag, i.e. DYKDDDDK tag), GABAA receptor subunit α2 (Gabra 2), 
and the neuronal nuclear antigen NeuN (Rbfox3 RNA binding protein, fox-1 
homolog (C. elegans) 3) as a marker for neurons were performed. Antibodies and 
dilutions used are summarized in table 8. 
Sections were deparaffinized in xylene two times for 5min each, followed by 
rehydration for two times 5min per step in a descending ethanol (99%, and 95%) to 
water series. For subsequent antigen retrieval, slides were heated in 0.01M citric acid 
solution at pH 6 (Sigma-Aldrich, Saint Louis, MO, USA) in a microwave oven three 
times for 5min intervals.  
Following three short washing steps in PBS (137mM NaCl, 2.7mM KCl, 10mM 
Na2HPO4 • 2 H2O, 2.0mM KH2PO4, pH 7.4), slides were incubated in 5% BSA in 
PBS-T (PBS supplemented with 0.1% v/v Triton X-100, Sigma Aldrich, Saint Louis, 
MO, USA) for 1h at RT for blocking. During the blocking step, antigen binding 
sides are saturated and as a consequence, binding of the antibodies to their target 
antigens is favored during the subsequent incubation in antibody solution. Primary 
antibodies diluted in 3% BSA in PBS-T and 3% BSA in PBS-T without added 
antibody for negative controls, respectively, were incubated with the tissue samples 
over night at 4°C in a humid chamber. Following two short rinsing steps in PBS-T, 
slides were washed in PBS-T three times for 5min. Secondary fluorochrome-coupled 
antibodies (summarized in table 8) diluted 1:500 in 3% BSA in PBS-T were 
incubated with the samples for 1h at room temperature. 
For double stainings, slides were washed three times in PBS-T before repeating 
blocking, primary, and secondary antibody incubations for the respective second 
antibody as described above. Hoechst solution (bisBenzimide H 33258, Sigma 
Aldrich, Saint Louis, MO, USA), diluted to 0.4μg/ml in PBS, was applied as 
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counterstaining for nuclei. Before and following Hoechst-staining, slides were 
washed in PBS-T three times. Slides were mounted using Dabco mounting solution 
(Sigma Aldrich, Saint Louis, MO, USA). Images were acquired using a Leica DM 
4500B fluorescence microscope (Leica Microsystems, Wetzlar, Germany). 
Antibody Reference  
number 
Species Clonality Company Dilution 
Primary antibodies 
α- GABAA α2 AGA-002 rabbit polyclonal Alomone labs, 
Jerusalem, Israel 
1:50 
α- NeuN MAB377 mouse monoclonal Merck Millipore, 
Billerica, MA, 
USA 
1:300 
α- PGC-1α ST1202 mouse monoclonal Merck Millipore, 
Billerica, MA, 
USA 
1:200 
α- 
DYKDDDDK 
tag 
2368 rabbit polyclonal Cell Signaling 
Technology, Inc., 
Danvers, MA, 
USA 
1:100 
Secondary antibodies (Alexa Fluor conjugated) 
α-  mouse      
Alexa Fluor 594 
A-21203 donkey polyclonal Invitrogen, 
Carlsbad, CA, 
USA 
1:500 
α-  rabbit       
Alexa Fluor 488 
A-21206 donkey polyclonal Invitrogen, 
Carlsbad, CA, 
USA 
1:500 
Table 8 Antibodies and dilutions for IHC. 
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4. Results 
4.1. Optimization of the qPCR system 
4.1.1. Confirmation of primer specificity 
Prior to measurement of gene expression, reaction conditions were optimized for 
each of the reference and target genes. Since changes in expression levels in mature 
neurons are known to be relatively limited, it was important to ensure accurate 
quantification of mRNA levels in order to be able to detect possible small changes in 
gene expression levels. (Elstner et al. 2011)  
As a first step, most of the primer pairs were found to bind specifically to their 
respective target genes and reliably mediate formation of specific products of the 
expected lengths in the qPCR reactions. However, for the target genes Atg3, Cox5b, 
Ndufa13, and PGC1α, an unspecific additional product was detected. Each of these 
additional products was found to be longer than the specific product, as shown in 
figure 6. 
  
Figure 6 Agarose gel electrophoresis of qPCR products. qPCR products were run on a 1% agarose gel (100V, 
75min). In addition to the respective specific products, reactions for each of the target genes produce 
additional, longer products (* unspecific products). 
For the above mentioned target genes, reaction conditions had to be modified to 
eliminate formation of unspecific products. For these genes, the extension time (10s 
at 72°C) was removed from the amplification step of the qPCR reaction (see table 6). 
This renders the binding conditions for the primers more stringent. As a 
consequence, binding to the specific target sequence is favored over binding to 
unspecific sequences. In addition, different combinations of sense and antisense 
primer concentrations were tested for specificity of amplification product formation. 
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For the target genes Atg3, Cox5b, and Ndufa13, this approach resulted in sufficiently 
increased specificity for the targeted sequence to rule out formation of unspecific 
products, while maintaining reaction sensitivity. 
For PGC-1α, however, an additional product slightly longer than the expected qPCR 
product was present even under modified conditions. Neither modification of the 
primer concentrations and their combinations nor adapting the annealing temperature 
resulted in formation of a single specific product. Representative gel images of PCR 
products formed under different reaction conditions are shown in figure 7a 
(modification of sense and antisense primer concentrations and their combination) 
and b (modification of the temperature during the annealing step of the amplification 
program).  
 
 
Figure 7  Modification of reaction conditions for PGC-1α. Formation of specific and unspecific amplification 
products was assessed qualitatively with agarose gel electrophoresis under modified reaction conditions. 
Shown are representative images of PCR products for hippocampal samples of wt controls. PCR products were 
run on 2% agarose gels (100V, 65min). PCR reaction conditions were as described in chapter 3, with 
modification of A. Primer concentrations (as given above) and B. annealing temperatures during the 
amplification step (as given above).  
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Blast search with the primer sequences (comparing to RefSeq RNA) revealed that 
the primer pairs for PGC-1α bind to two variants of the transcript of the PGC-1α 
gene (compare figure 8). The primers target transcript variant 1 (NCBI Reference 
Sequence: NM_008904.2), which encodes mRNA for PGC-1α. In addition, the 
primer pairs also recognize transcript variant 2 (NCBI Reference Sequence: 
NR_027710.1), which constitutes a non-coding mRNA. 
 
Figure 8 Blast sequence alignment of transcript variants of PGC-1α detected by the primers in use for qPCR. 
Blast sequence alignment to RefSeq RNA, variant 1: PGC-1 mRNA encoding transcript, variant 2: PGC-1 
noncoding mRNA. Identities = 6464/6495 (99%), Gaps = 31/6495 (0%). Squares mark the region of primer 
binding (S: sense, AS: antisense). 
The additional product thus most likely reflects a splice variant of the PGC-1α 
mRNA. The difference in sizes of the specific (80 bases) and additional product 
(~110 bases) as reflected by the bands detected in agarose gel electrophoresis (see 
figure 7), corresponds to the size of the additional region present in transcript variant 
2. Except for this region, both splice variants have a similar nucleotide sequence and 
are both detected with equal sensitivity and specificity by the primers in use. For this 
reason, it was not possible to modify primer binding conditions in such a way as to 
favor binding to one transcript variant over the other.  
The formation of an additional product in the qPCR reaction is also reflected in the 
melting temperature analysis. After the amplification reaction of the qPCR, a 
temperature gradient is applied while constantly measuring fluorescence intensity. 
The gradual increase ultimately causes products to dissipate at a temperature that 
reflects the binding affinity of both strands of the product. This melting point is 
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reflected by a steep decrease of fluorescence, since double stranded products 
dissipate into single stranded conformation. Apart from the melting temperature, the 
negative first derivative of the fluorescence intensity in dependence on the 
temperature is used to assess the specificity of product formation. Specific product 
formation commonly is reflected by a pronounced peak in the derivate. This 
corresponds to the temperature at which the decrease in fluorescence is steepest, and 
shows the dissipation of double stranded product. Additional peaks at lower 
temperatures reflect unspecific product formation, dissipating already at lower 
temperatures due to a lower binding affinity.  
A representative melting curve for qPCR amplification of PGC-1  is shown in 
figure 9. The specific product (mRNA encoding transcript variant 1) has a melting 
temperature of 79.3ºC, whereas the product reflecting noncoding transcript variant 2 
shows a decrease in fluorescence at a slightly lower temperature, having a melting 
temperature of 74.2 ºC.  
 
Figure 9 Melting curve analysis for PGC-1α. Melting analysis as performed with the LightCycler analysis 
software (Roche Diagnostics, Basel, Switzerland). The figure shows a representative image of a melting curve for 
qPCR amplification for PGC-1α (reaction conditions were as described in chapter 3). 
Transgene expression exclusively results in formation of coding variant 1, since the 
exogenous PGC-1α gene was inserted in form of cDNA reflecting only the protein-
coding transcript. Considering the fact that the additional product reflects a transcript 
variant of the endogenous PGC-1α gene encoding a non-coding mRNA, it is 
conceivable that the formation of this product does not interfere with a reliable 
detection of the gene expression levels. mRNA levels measured for PGC-1α 
comprise both the endogenous as well as the expression of the transgene. 
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Formation of a qPCR product specific for the target genes was assessed from the 
melting curves for each primer pair as well as by agarose gel electrophoresis of the 
qPCR products. This allows comparing the lengths of the products to the expected 
length of the amplified sequences and excluding the formation of additional, 
unspecific products. Amplification products of qPCR reactions for each of the 
reference and target genes in hippocampal and cortical samples of both wt and tg 
animals were run on agarose gels, as shown by representative gel images in figure 
10. Products of the qPCR reactions for reference genes actin β and GAPDH were 
formed in a similar way in both qPCR amplification programs in use. No differences 
could be observed between samples from PGC-1α tg and control mice. 
 
Figure 10 Formation of specific amplification products for reference genes. qPCR amplification products  for 
Actin β and GAPDH were run on agarose gels (2%, 60V, 60min). Shown are representative images for 
hippocampal sample.  A. wt control B. PGC-1α tg.  + qPCR program with extension time included in the 
amplification step, - qPCR program without extension time.  
Likewise, qPCR products for the target genes produced under the conditions used for 
gene expression measurements were analyzed electrophoretically. Figure 11 depicts 
a typical gel image.  
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Figure 11 Formation of specific amplification products for target genes. qPCR amplification products  for target 
genes were run on agarose gels (2%, 60V, 100min; for qPCR reaction conditions, see chapter 3). qPCR products 
were diluted to ensure optimal visualization) . Given here is a representative image for product analysis (Hc of 
PGC-1α tg mouse). 
A double band for PGC-1 could be observed in some qPCR reactions, but was not 
detectable throughout all gel images taken. Presumably, this is due to a higher 
relative amount of the specific product observed for the tg mice. As for the 
remaining target genes, formation of a single product was shown for PGC-1α tg and 
wt mice. Lengths of qPCR product were matching the expected qPCR products for 
the reference and target genes, as summarized in table 9. 
Gene Expected length of the product 
(bases) 
Actin β 95 
GAPDH 101 
Acly 91 
Atg3 93 
Atp5h 128 
Cox5b 98 
Cox7b 185 
Gabra2 149 
Gabrg2 99 
Gsr 108 
Ndufa13 77 
Nedd8 128 
PGC-1 80 
Rheb 138 
Sirt-1 74 
Uba3 93 
Table 9 Expected lengths of amplification products in qPCR. 
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4.1.2. Efficiency measurements 
Efficiencies of the qPCR reactions of the reference genes were assessed to ensure a 
comparable level of amplification efficiencies among samples from both control and 
tg mice for both reference genes. Efficiencies were measured in hippocampal mRNA 
samples. Preceding tests were performed to ensure comparability between Hc and 
Cx. Since these test measurements yielded highly similar results for both tissues, 
efficiency measurements were done using hippocampal mRNA. The efficiencies 
derived from these measurements were used for gene expression measurements in 
hippocampal and cortical samples. 
Efficiency calculations were based on cDNA input dilution series spanning several 
orders of magnitude. Cp values corresponding to the dilution steps are plotted 
against the decadic logarithm of the respective dilutions of cDNA input. Linear 
regression upon the measured data points yields a linear graph, from whose slope the 
reaction efficiency can be calculated. The relationship between efficiency and the 
slope of the regression line is given as follows, adapted from (Dorak 2006): 
  
  
  
 
          
 
In the equation, (eff) corresponds to the efficiency and 
  
  
 represents the slope. If a 
perfect doubling of template occurs during each cycle, the efficiency value equals 
2.0. In this case, the slope of the regression line is -3.32. The efficiency of the qPCR 
reaction corresponds to the rate of amplification. In case the efficiencies are 
exceedingly higher or lower, the reaction conditions most likely are not suitable for 
ensuring a reliable amplification and detection. (VanGuilder, Vrana & Freeman 
2008, Dorak 2006) 
Efficiencies vary in dependence on the length of the qPCR product and the base 
composition, among other factors. One of the main influencers of efficiency is the 
cDNA concentration in the starting reaction. For this reason, the dynamic range is an 
important parameter for qPCR performance. This range corresponds to the cDNA 
concentrations that can be used as input and result in comparable and reliable qPCR 
reactions.  
qPCR was performed using cDNA concentrations spanning four orders of magnitude 
as input in order to assess the dynamic range of the qPCR reactions. Reaction 
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effiencies were calculated from a linear regression analysis based on the Cp values 
obtained for a number of cDNA dilutions within the above mentioned range.  
For reference genes, this resulted in efficiencies ranging from 1.95 to 2.07. These 
values are very close to the ideal reaction, which would correspond to 2.00, and the 
amplification reactions can be considered to yield highly reliable results over the 
dynamic range of four orders of magnitude. Slightly different patterns were observed 
for the amplification of GAPDH from mRNA of tg mice under amplification 
conditions including an extension step. Here, a higher efficiency (2.22) was 
observed. Especially in view with the high reliability of the remaining reactions, this 
value as determined to lie within the acceptable range. 
Gene 
 
Efficiency Slope 
+ (with extension time) 
Actin β control 1,96 -3,419 
  PGC-1α tg 2,05 -3,213 
GAPDH control 1,97 -3,407 
  PGC-1α tg 2,22 -2,884 
–  (without extension time) 
Actin β control 1,98 -3,38 
  PGC-1α tg 2,07 -3,158 
GAPDH control 1,95 -3,459 
  PGC-1α tg 1,98 -3,369 
Table 10 Efficiencies of qPCR reactions for reference genes.  
Figure 12 shows the efficiency curves for both reference genes for wt and PGC-1  
tg mice under both measurement conditions in use. Regression lines of Cp values 
plotted against the range of cDNA dilutions used to determine the reaction 
efficiencies are depicted.  
The efficiencies for reference genes can be considered to have comparable levels 
among wt control and PGC-1 tg mice as well as in both qPCR programs used (for a 
summary of reaction conditions and program setup see chapter 3). 
For measurements of gene expression levels, a final cDNA dilution of 1:500 in the 
reactions (indicated in the graphs by arrows) was used for all of the target genes. 
This cDNA concentration lies well within the linear range of the qPCR assay. As 
shown in figure 12, this cDNA dilution is within the range in which all of the 
efficiency functions lie close together within a very narrow range. 
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Figure 12 Efficiencies of qPCR reactions for reference genes. Shown are regression curves for efficiencies of 
reference genes A. Actin β and B. GAPDH. + qPCR program run with extension time during the amplification, - 
qPCR program without extension time. 
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qPCR products were run on agarose gels to assess reaction specificity as described in 
chapter 3. Reactions with cDNA dilutions spanning four orders of magnitude as 
input were shown to produce specific products at the expected lengths for both 
reference genes. This held true for control and PGC-1 tg mice. Equally, removing 
the extension step from the amplification reaction of the qPCR program did not 
interfere with the specific formation of products. 
Similar to the approach used for the reference genes, reaction efficiencies were 
tested for all genes of interest over a range of two to four orders of magnitude. 
Dilution ranges and measurement points were chosen in dependence on theoretical 
estimations of expression levels and preceding qPCR test runs. Reaction conditions 
can be found in chapter 3. Efficiencies are summarized below in table 11: 
Gene 
qPCR 
program efficiency slope 
Acly + 1.93 -3.512 
Atg3 + 1.92 -3.519 
Atp5h 
– 
2.00 -3.331 
Cox5b 
– 
1.92 -3.525 
Cox7b + 2.15 -3.017 
Gabra2 + 2.05 -3.209 
Gabrg2 + 1.90 -3.579 
Gsr + 1.90 -3.580 
Ndufa13 
– 
1.91 -3.572 
Nedd8 + 1.76 -4.059 
PGC-1 
– 
2.07 -3.170 
Rheb + 1.85 -3.732 
Sirt-1 + 1.97 -3.408 
Uba3 + 1.96 -3.431 
Table 11 Efficiencies of qPCR reactions for target genes. + qPCR program run including extension time during 
the amplification step, - qPCR program run without extension time. 
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The efficiencies given here have been measured using hippocampal RNA of wt 
mice. Test measurements comparing hippocampal and cortical expression of the 
target genes in both wt as well as tg mice were performed to ensure comparability.  
In consideration of the parameters determined in the optimization process described 
above, final conditions for measurements of gene expression were chosen (as 
described in chapter 3.).  
Efficiencies were taken into account for calculation of relative expression levels. 
Calculations were based on the ΔΔCp method, as reviewed in chapter 1.5. 
 
4.2. Gene expression analysis 
4.2.1. Expression analysis of PGC-1 
The initial study characterizing the PGC-1α tg mouse line revealed a strong increase 
in PGC-1α protein levels in SNc of tg mice. Exogenous PGC-1α was strongly 
expressed throughout the studied brain regions. (Mudo et al. 2012) Equally, a 
microarray based screening (GeneChip Mouse Exon ST Array, Affymetrix, Santa 
Clara, CA, USA), showed increased expression of PGC-1α in Hc and Cx of tg mice. 
In order to further characterize gene expression patterns in PGC-1α tg mice, we 
assessed expression levels of PGC-1α mRNA. This includes expression of both the 
endogenous gene as well as expression driven by the transgene.  
 
Figure 13 Gene expression analysis for PGC-1α in Hc. Relative expression levels in Hc of PGC-1α tg mice,            
± standard deviation (stdev). Stars denote statistical significance compared to wt controls ( *** p<0.001). 
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As expected, PGC-1α expression is increased in Hc of tg mice. The average increase 
amounts to 1.90 ± 0.55.  This expression value is, as all of the following values, 
given as average expression among the PGC-1α tg mice in comparison to wt controls 
(set to 1.00). Errors are denoted as standard deviation (stdev). 
The high standard deviation can be attributed to individual differences in gene 
expression levels that were found among the PGC-1α tg mice.  
PGC-1α mRNA expression levels in cortical samples of tg mice paralleled the 
findings in Hc, with a pronounced increase in the expression levels of PGC-1α being 
detected. The expression levels are slightly lower than in Hc, averaging to 1.79 ± 
0.45 as compared to wt mice. 
 
Figure 14 Gene expression analysis for PGC-1α in Cx. Relative expression levels in Cx of PGC-1α tg mice,             
± stdev. Stars denote statistical significance compared to wt controls (*** p<0.001). 
Next, we sought to determine immunohistochemically whether the increase in PGC-
1α mRNA levels entails higher protein levels.  
Endogenous PGC-1α expression in the brains of wt mice has been characterized 
previously. (Tritos et al. 2003) The characterization was done for the strain that 
constitutes the wt controls and genetic background of tg mice for this study. In line 
with the findings reported by Tritos and collegues, widespread expression of PGC-
1α in Hc of wt controls was observed. (Tritos et al. 2003) Immunostaining for PGC-
1α targets both endogenous as well as the transgenic protein, and the overall 
expression pattern did not appear to differ between wt controls and PGC-1α tg mice.  
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As the expression levels measured by qPCR comprise both the endogenous as well 
as the transgene driven mRNA expression for PGC-1α, we sought to verify the 
presence of exogenous PGC-1α in the tg mice.  
Exogenous PGC-1α protein is expressed with a flag-tag, and can therefore be 
distinguished immunohistochemically from the endogenously expressed PGC-1α. 
(Mudo et al. 2012) Simultaneous immunohistochemical detection of NeuN as a 
neuronal maker and flag-tag, marking exogenous PGC-1α, was performed in order to 
study the expression pattern of transgenic PGC-1α in hippocampal and cortical 
neurons. Representative images are shown in figure 15. 
Immunohistochemical staining for flag-tag revealed a widespread expression of 
exogenous PGC-1α in hippocampal and cortical neurons of PGC-1α tg mice, as 
shown by colocalization of NeuN and flag-tagged PGC-1α. In contrast, no signal for 
flag-tag could be detected in the wt controls.  
Furthermore, immunostainings for PGC-1α and flag-tag were performed. In 
accordance with the results presented above, signals for PGC-1α and flag were 
colocalized to the same cells throughout the Hc and Cx of PGC-1α tg mice, as shown 
by representative images in figure 16. 
An interesting aspect of transgene driven PGC-1α expression that was revealed by 
immunostainings is the subcellular expression pattern. Whereas PGC-1α staining 
was located mostly to the nuclei of neurons, flag-tag positive PGC-1α staining rather 
appeared to accumulate in close proximity to, but outside of the nucleus.  
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Figure 15 Colocalization analysis for NeuN and flag-tagged exogenous PGC-1α. Immunostainings for the 
neuronal marker NeuN and flag-tag as a surrogate marker for exogenous PGC-1α in A. Hc and B. Cx. Upper 
panels (control): wt controls, lower panels (PGC-1 tg): PGC-1α tg mice. 20x magnification, scale bar 100μm.  
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Figure 16 Colocalization analysis for PGC-1α and flag-tagged exogenous PGC-1α. Immunostainings for PGC-1α  
and flag-tag as a surrogate marker for exogenous PGC-1α in A. Hc and B. Cx. Upper panels (control): wt 
controls, lower panels (PGC-1 tg): PGC-1α tg mice. 20x magnification, scale bar 100μm. 
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These findings show that transgenic introduction of the PGC-1α gene causes flag-
tagged exogenous PGC-1α to be expressed in hippocampal and cortical neurons in 
the PGC-1α tg mouse line. This is in line with the characterization studies of 
transgene expression in substantia nigra reported by Mudò et al. (Mudo et al. 2012) 
Pronounced increases in mRNA levels of PGC-1α parallel the presence of exogenous 
PGC-1α in neurons in both tissues studied in this Master’s thesis study.  Insertion of 
the transgene causes increases in the transcription of PGC-1α, with the mRNA 
population reflecting expression of both endogenous as well as exogenous PGC-1α. 
The enhanced mRNA transcription can therefore at least partly be attributed to 
expression of the transgene.  
Mudò et al showed that the PGC-1α transgene expression entails increased protein 
levels in substantia nigra. Taking this into account, the above described findings 
suggest that the increase in transcriptional activity likely is reflected by higher 
amounts of PGC-1α on the protein level in Hc and Cx. (Mudo et al. 2012) 
Similarly and expectedly, the transgene expression is reflected by the presence of 
flag-tagged PGC-1α in neurons. Therefore, changes in gene expression levels can 
most likely be attributed to neurons. 
A surprising observation in hippocampal and cortical sections of tg mice were the 
presence of strongly PGC-1α and flag positive extranuclear signals taking on 
elongated forms. This, translation into protein and PGC-1α activity levels under 
transgene expression remain to be studied.  
PGC-1α activity is known to be directly regulated by the deacetylase Sirt-1. (Canto, 
Auwerx 2009) We hypothesized that PGC-1α overexpression might have an 
influence on gene expression of Sirt-1 via possible feedback loops.  The expression 
levels of Sirt-1 in Hc were therefore measured. 
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Figure 17 Gene expression analysis for Sirt-1 in Hc. Relative expression levels in Hc of PGC-1α tg mice,                 
± stdev. Stars denote statistical significance compared to wt controls (* p<0.05). 
Sirt-1 1 mRNA levels showed a small, but significant decrease in Hc of tg mice. 
mRNA expression was 0.95 ± 0.06 in tg mice as compared to wt controls.  
 
4.2.2. Partial downregulation of mitochondrial metabolic enzymes  
Given that PGC-1α is a known master regulator of mitochondrial metabolism, and 
obtains an essential function to maintain energetic homeostasis in neurons, we asked 
whether PGC-1α overexpression has a long-term impact on mitochondrial oxidative 
phosphorylation. (Kelly, Scarpulla 2004, Puigserver, Spiegelman 2003, Wareski et 
al. 2009) We hypothesized that PGC-1α overexpression might entail sustained 
changes in metabolic activity in the brains of tg mice that are attributable to 
transcriptional regulation.  
In order to encompass possible gene expression changes along oxidative metabolism 
pathways, we chose a number of genes encoding for enzymes catalyzing reactions at 
different stages of metabolism. Reviewed in (Duchen 2004, Nunnari, Suomalainen 
2012, Abou-Sleiman, Muqit & Wood 2006) 
These included, firstly, citrate lyase (Acly), the enzyme producing acetyl-CoA by 
cleavage of citrate. The enzyme itself is located in the cytosol, but its substrate and 
product are produced and metabolized, respectively, in mitochondria. Acetyl-CoA 
provides the link between glucose and fatty acid metabolic pathways, and is integral 
part of cellular respiration. It enters the citric acid cycle, which in turn yields the 
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electron carriers NADH and FADH2 fuelling the mitochondrial electron transport 
chain. (Chypre, Zaidi & Smans 2012) 
Furthermore, genes encoding respiratory chain subunits were chosen:  
NADH dehydrogenase 1α is the entry enzyme for electrons transferred by NADH 
into the respiratory chain. (Duchen 2004) Disturbances in complex I functionality 
have been linked to neurodegeneration and are strongly implicated in PD 
pathogenesis. (Winklhofer, Haass 2010)  The complex I inhibitor MPTP is used as a 
means to induce parkinsonism in animal models. (Przedborski et al. 2004) 
Furthermore, PGC-1α overexpression is protective against MPTP treatment in tg 
mice. (Mudo et al. 2012) As a representative subunit of this complex, subunit 13 
(Ndufa13) was chosen for gene expression studies. 
Complex IV, cytochrome c oxidase, has been implicated in oxidative stress 
generation. (Srinivasan, Avadhani 2012) Hypothesizing that PGC-1α mediated 
neuroprotection might involve changes in expression of ETC complexes, we chose to 
include two subunits of complex IV, cytochrome c oxidase into our studies. Here, 
gene expression of subunits Vb (Cox5b) and VIIb (Cox7b) was measured.  
Since PGC-1α tg mice showed an increased respiratory control, the site of actual 
ATP production, F1FO ATP synthase, was of interest. (Duchen 2004, Mudo et al. 
2012) Gene expression was measured for ATP synthase, H
+
 transporting, 
mitochondrial Fo complex, subunit d (Atp5h). 
 
Figure 18 Gene expression analysis of enzymes involved in mitochondrial energy metabolism in Hc. Relative 
expression levels in Hc of PGC-1α tg mice, ± stdev. Stars denote statistical significance compared to wt controls 
(* p<0.05, ** p<0.01, *** p<0.001). 
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Strikingly, gene expression levels of all of the above named enzymes involved in 
energy metabolism were found to be either reduced or unchanged in Hc of PGC-1α 
tg mice. 
Acly was found to be slightly, but significantly downregulated (0.90 ± 0.12).  A 
more pronounced underexpression was found for Ndfua13, averaging at 0.64 ± 0.23. 
No differences between PGC-1α tg and wt mice could be detected in the expression 
of Cox5b. In contrast to the latter finding, mRNA for Cox7b was strongly 
underexpressed in PGC-1α tg mice, at an average of 0.55 ± 0.33 of control 
expression.  
 
Figure 19 Gene expression analysis of enzymes involved in mitochondrial energy metabolism in Cx. Relative 
expression levels in Cx of PGC-1α tg mice, ± stdev. Stars denote statistical significance compared to wt controls 
(** p<0.01). 
Similar to the findings in hippocampal tissue, gene expression of respiratory chain 
enzyme subunits was either unchanged or decreased in cortical samples. Here, no 
difference could be measured in mRNA levels reflecting citrate lyase expression. 
Equally, and similarly to the findings in hippocampal RNA extracts, Atp5h 
expression was unaffected by PGC-1α overexpression.  
However, in a strong similarity to the findings in Hc, also Cx of PGC-1 α tg mice 
showed strong underexpression of Ndufa13 (0.68 ± 0.27) and Cox7b (0.44 ± 0.46). 
The small decrease of Acly expression in Hc, as well as the unchanged expression in 
Cx were paralleling the microarray based results. Similarly, Cox7b underexpression 
had been indicated by microarray results for Hc, but not Cx.  
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Cox5b, Ndufa13, and Atp5h had been indicated to be slightly upregulated by the 
microarray. These values could not be confirmed with the qPCR based 
measurements. 
 
4.2.3. Upregulation of the mitochondrial antioxidant system 
Representative of the mitochondrial antioxidant system known to be under the 
regulation of PGC-1α, expression levels of glutathione reductase (Gsr) were 
measured. (Nicholls 2002) 
 
Figure 20 Gene expression analysis for Gsr. Relative expression levels of Gsr in A. Hc and B. Cx of PGC-1α tg 
mice, ± stdev; stars denote statistical significance compared to wt controls (* p<0.05, *** p<0.001). 
Similar small but significant increases in the expression level in Hc (1.11, Stdev 
0.08) as well as Cx (1.07, Stdev 0.10) of tg mice were observed. These findings 
parallel the upregulation found with the microarray based study, even though these 
screening results indicated a higher increase in gene expression. 
 
4.2.4. Expression analysis of nonmitochondrial pathways implied in Parkinson’s 
Disease  
In order to assess influences of PGC-1α overexpression on pathways involved in the 
regulation of neuronal survival by growth factors and nutrient sensing networks, we 
measured mRNA levels of the Ras-family member protein Ras homolog enriched in 
brain (Rheb). Rheb is part of the mTOR signaling pathway and known to be 
underexpressed in DA neurons in PD. (Lee, Giordano & Zhang 2012, Elstner et al. 
2011)  
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Figure 21 Gene expression analysis for Rheb in Hc. Relative expression levels of Rheb in Hc of PGC-1α tg mice, 
± stdev. Stars denote statistical significance compared to wt controls (* p<0.05). 
In Hc samples of tg mice, Rheb was somewhat underexpressed (0.87 ± 0.15) in 
comparison to wt mice, confirming values measured by microarray. 
mTOR signaling is involved in the regulation of autophagy. Due to the known role 
of protein scavenging and degradation in PD pathogenesis, we were interested in 
possible changes of regulatory protein modifications under PGC-1α overexpression. 
(Kim, Rodriguez-Enriquez & Lemasters 2007, Lee, Giordano & Zhang 2012) 
Expression levels of autophagocytosis associated protein 3 (Atg3) were measured in 
Hc of tg mice. Atg3 has a role in mediating autophagocytotic degradation of 
organelles, and is a ubiquitin-like modifier. (Lee, Giordano & Zhang 2012) 
 
  
Figure 22 Gene expression analysis for Atg3 in Hc. Relative expression levels of Atg3 in Hc of PGC-1α tg mice, ± 
stdev. Stars denote statistical significance compared to wt controls (** p<0.01). 
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With average expression levels of 0.92 ± 0.07 in PGC-1α tg mice, Atg3 showed a 
small, but significant underexpression.  
Ubiquitin-like modifier activating enzyme 3 (Uba3) mediates activation of Neural 
precursor cell expressed, developmentally down-regulated 8 (Nedd8). This pathway, 
among others, influences cell cycle progression. (Gong, Yeh 1999, Kamitani et al. 
1997) 
  
Figure 23 Gene expression analysis for Uba3 in Hc. Relative expression levels of Uba3 in Hc of PGC-1α tg mice, 
± stdev. Stars denote statistical significance compared to wt controls (** p<0.01). 
In Hc of PGC-1α tg mice, Uba3 expression was slightly reduced (0.90 ± 0.08).   
  
Figure 24 Gene expression analysis for Nedd8 in Hc. Relative expression levels of Nedd8 in Hc of PGC-1α tg 
mice, ± stdev. 
Nedd8 mRNA levels in Hc showed no detectable differences between PGC-1α tg 
and wt mice.  
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The expression values for Atg3, Uba3, and Nedd8 are somewhat contradictory to a 
slight upregulation indicated by the microarray. 
 
4.2.5. Differential expression of GABAA receptor subunits 
The microarray based screening revealed a pronounced upregulation of subunit α2 of 
the GABAA receptor. In accordance with reports about involvement of PGC-1α in 
the regulation of survival of GABAergic neurons in rat brain and differential 
regulation of GABAA receptor subunits in neurodegenerative diseases, PGC-1α 
overexpression seemed to be altering the expression of at least two subunits. 
(Cowell, Blake & Russell 2007, Luchetti, Huitinga & Swaab 2011) For this reason, 
we sought to verify the differential regulation for GABAA receptor subunits α2 
(Gabra2) and γ2 (Gabrg2). 
 
   
Figure 25 Gene expression analysis for Gabra2 and Gabrg2 in Hc. Relative expression levels in Hc of PGC-1α tg 
mice, ± stdev. Stars denote statistical significance compared to wt controls (*** p<0.001). 
In line with the microarray results, indicative of an approximately 2.5 fold increase 
compared to wt controls, Gabra2 was found to be highly upregulated in Hc of PGC-
1 tg mice. The average expression level in comparison to wt controls was 2.24 ± 
0.55.   
In contrast, the upregulation could not be verified for Gabrg2. Expression was found 
to be decreased in a highly significant manner to 0.76 ± 0.18 in comparison to wt 
controls, whereas the microarray results had pointed towards a slight upregulation (in 
the screening, an expression value of 1.21 in tg mice was reported). 
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These findings suggest a strong relative shift in the subunit composition of GABAA 
receptors, with an increased number 2 containing receptors present in brains of tg 
mice. To further characterize the strong upregulation of GABAA receptor subunit 2 
expression, we sought to determine expression patterns in Hc 
immunohistochemically. Representative images for colocalization studies of Gabra2 
with NeuN and PGC-1α, respectively, are shown in figure 26. 
 
Figure 26 Localization analysis for Gabra2 in Hc. A. Colocalization analysis for NeuN and Gabra2. 
Immunostainings for the neuronal marker NeuN and Gabra2. B. Colocalization analysis for PGC-1 and Gabra2. 
Immunostainings for PGC-1 and Gabra2. Upper panels (control): wt controls, lower panels (PGC-1 tg): PGC-
1α tg mice. A. and B. 20x magnification, C. 100x magnification, scale bar 100μm. C. Subcellular localization of 
Gabra2. Magnification of the area marked in B. 
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Gabra2 was found to be expressed throughout the Hc of both wt and PGC-1α tg 
mice. Expression appeared to be restricted to neuronal nuclei, as shown in figure 26 
A by colocalization of the neuronal nuclear antigen NeuN and Gabra2. A small 
number of cells seemed, however, to express long processes staining positive for 
both NeuN and Gabra2.  
An expression study in rat brain has shown strong expression of PGC-1α in 
GABAergic neurons in Hc and Cx. (Lucas et al. 2010) It has been suggested that 
PGC-1α is an essential influencer of survival and homeostasis maintenance in 
GABAergic neurons in developing and adult rat brains. (Cowell, Blake & Russell 
2007, Lucas et al. 2010) 
We hypothesized that this relationship may be important in PGC-1α tg mice and 
have a possible involvement in conferring neuroprotective properties of PGC-1α 
overexpression.  
In immunostainings of hippocampal sections of wt mice, virtually all Gabra2 
positive neurons were found to be expressing PGC-1α. The signals appeared to be 
closely colocalized, and a large fraction of the signals were directly overlapping, as 
shown in figure 26 B. This pattern was observed as well in hippocampi of tg mice. 
However, and unexpectedly, in PGC-1α tg mice, Gabra2 positive signals appeared 
outside the soma in the shape of prolonged processes and were observed mainly in 
Hc (compare figure 26 C). All extrasomatic Gabra2 signals overlapped with PGC-1α 
positive staining. Stainings suggest a higher number of hippocampal neurons 
expressing Gabra2 in the tg as compared to the wt mice. However, this needs to be 
studied in quantitative manner in the future. 
Similarly, we studied the expression of GABAA receptor subunits in cortical samples 
of tg mice. Expression of Gabra2 is highly increased in Cx, averaging 1.72 ± 0.41. 
The high standard deviation originates from individual differences in expression 
levels among the tg mice. In contrast, Gabrg2 is underexpressed (0.74 ± 0.09). This 
parallels the findings in Hc, even though the increase in Gabra2 is not as pronounced 
in Cx of tg mice.  
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Figure 27 Gene expression analysis for Gabra2 and Gabrg2 in Cx. Relative expression levels in Cx of PGC-1α tg 
mice, ± stdev. Stars denote statistical significance compared to wt controls (*** p<0.001). 
Similar analyses of expression patterns on the protein level were performed in 
cortical sections. The expression of Gabra2 in the Cx of PGC-1α tg mice appeared 
very similar to the hippocampal staining pattern: in both controls and tg animals, 
Gabra2 was colocalized with the neuronal marker NeuN, being expressed in the 
nuclei of neurons (compare figure 28 A). 
Gabra2 positive neurons were closely colocalized with PGC-1α. Virtually all of the 
nuclei of GABAergic neurons showed strong PGC-1α expression. Representative 
images are shown in figure 28 B.  
In addition, some of the neurons appeared to be expressing long processes with 
strong Gabra2 staining and positive signal for PGC-1α.  
Interestingly, the number of Gabra2 positive neurons in Cx seemed to be 
considerably higher in tg than in wt mice. This remains to be assessed in more detail 
in future experiments.  
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Figure 28 Localization analysis for Gabra2 in Cx. A. Colocalization analysis for NeuN and Gabra2. 
Immunostainings for the neuronal marker NeuN and Gabra2. B. Colocalization analysis for PGC-1 and Gabra2. 
Immunostainings for PGC-1 and Gabra2. Upper panels (control): wt controls, lower panels (PGC-1 tg): PGC-
1α tg mice. 20x magnification, scale bar 100μm. 
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5. Discussion 
5.1. Technical aspects of the system 
5.1.1. Comparison of microarray and qPCR 
 
Figure 29 Comparison of relative gene expression levels measured by microarray and qPCR A. in Hc, B. in Cx. 
Comparing the initial screening results found in the microarray based study with the 
expression levels measured by qPCR, it is obvious that the results differ partly. For 
the genes with the most pronounced differential regulation, the tendencies could be 
confirmed by qPCR, even though the expression values differ somewhat. 
In direct comparison, the expression levels measured by microarray appear to be 
somewhat higher than the values measured with qPCR throughout most of the genes, 
as shown figure 29. Strikingly, the expression of PGC-1α was underestimated by the 
microarray. For genes with very small increase or reduction in expression levels, the 
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findings of microarray and qPCR are somewhat contradictory. Since the microarray 
appears to generally estimate the expression values higher than the qPCR based 
system, small increases identified with the microarray screening consistently 
translate to slightly decreased mRNA levels in the qPCR measurements.  
The differences in gene expression levels seem to be due to a systematic difference. 
As described in chapter 4.1., the qPCR system setup used for gene expression 
measurements in this study was optimized for each of the target genes. This ensures 
highly reliable, specific targeting of the genes of interest and rules out false positives 
due to unspecific binding. The qPCR setup was optimized to be highly specific for 
mRNAs transcribed from the genes of interest. Primers were designed to target 
mRNAs in a highly specific manner, and gene expression levels were normalized to 
average values of two reference genes known to be expressed at similar, stable levels 
in the control and tg mice. The normalization levels out small differences in cDNA 
input amounts and pipetting errors. Crossreactivity with other mRNAs, which would 
result in unspecific binding and false positive results, was ruled out. Due to the 
sequence recognition setup in microarrays, crossreactivity between different targets 
is more likely. (Draghici et al. 2006) 
Microarrays are still mainly used for screening purposes, as was the case in this 
study. The main advantage of microarrays is a large-scale, rapid screening process, 
whereas qPCR is more labor-intensive, but produces more reliable results. 
(VanGuilder, Vrana & Freeman 2008, Draghici et al. 2006) 
A biological aspect to be considered is that the detection of differential regulation is 
more difficult in mature neurons than in many other cells. This is based on the fact 
that mature neurons generally undergo very small changes in expression activity 
(Elstner et al. 2011) Due to the small effect size, it is difficult to reliably detect 
changes.  
For these reasons, the qPCR based system may be considered more reliable in 
detecting small differences in expression levels, and more suitable for expression 
analysis in brain samples. 
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5.1.2. Biological factors to be taken into account 
5.1.2.1. Interpretation of mRNA expression data 
This study aimed at further characterizing gene expression networks in Hc and Cx of 
PGC-1α tg mice. The characterization was focused on the mRNA expression.  
However, differential expression is not necessarily translated into equal changes in 
protein levels. The expression values found in this study provide a measure to 
identify PGC-1α target genes. Equally, it is possible to draw conclusions about the 
effect of PGC-1α overexpression on the studied gene expression networks and their 
transcriptional activity.  
Adding to previous findings, our results suggest that the changes in mRNA levels 
reported here are also reflected by differential expression on the protein level. (Mudo 
et al. 2012) 
In this study, we aimed at identifying targets of PGC-1α regulation that are 
differentially expressed on the mRNA level. Conclusions about the influence of the 
expression changes reported here on the activity and functionality of the molecular 
pathways, however, are preliminary and will have to be assessed experimentally.  
 
5.1.2.2. Mitochondrial biology 
In this study, expression levels were normalized to the average expression of two 
reference genes located in the cytosol of cells. The expression levels can therefore be 
considered as an average per cell.  
PGC-1α has been shown to regulate mitochondrial density in neurons. (Wareski et 
al. 2009) At present, it is only possible to speculate about the influences of PGC-1α 
on mitochondrial number in neurons of the PGC-1α tg mouse line. It is well possible 
that PGC-1α overexpressing neurons possess higher numbers of mitochondria. It is 
conceivable that PGC-1α not only influences the mitochondrial number, but possibly 
exerts its neuroprotective effects via enhancing mitochondrial functional state.  
For future projects, it would be interesting to measure protein levels, normalized to 
the number of mitochondria per cell, in order to estimate the functional state of 
mitochondria. 
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5.1.2.3. Cell population for measurements 
Whole tissue hippocampal and cortical samples were used for analysis. As a 
consequence, the reported values reflect an average of expression patterns over 
neurons as well as glial cells. Expression of exogenous PGC-1α is restricted to 
neurons via the use of the specific Thy1.2 promoter in the tg mice. (Vidal et al. 1990, 
Caroni 1997) Therefore, the changes in gene expression levels reported in this study 
can be attributed to PGC-1α regulated changes in neuronal gene expression 
networks. However, glial cells may as well be influenced by expression patterns in 
adjacent neurons, which may result in changes in gene expression. This possible 
confounding factor can be excluded by studying gene expression specifically in 
neurons of PGC-1α tg mice.  
DA neurons are more vulnerable to dysregulations in cellular homeostasis than other 
neurons. They are the predominant target of pathological changes in both models as 
well as clinical studies of neurodegeneration in PD. (Zheng et al. 2010) 
This points towards a particularly important role of PGC-1α regulated gene 
expression networks in DA neurons.  For further analysis of the role of PGC-1α 
expression in the cell viability of DA neurons, specific analysis of mRNA and 
protein levels could be performed.  
 
5.2. Implications for PGC-1 regulated molecular pathways 
5.2.1. Expression analysis of PGC-1α 
This study has confirmed the overexpression of PGC-1α in Hc and Cx of tg mice on 
the mRNA level. As shown immunohistochemically, transgene driven expression of 
PGC-1α results in translation into protein, and the presence of exogenous PGC-1α in 
hippocampal and cortical neurons of PGC-1α tg mice was confirmed. 
This reflects the findings reported by Mudò and coworkers. In their study 
characterizing the PGC-1α tg mouse line, increased protein levels of PGC-1α were 
found in striatum and substantia nigra.  (Mudo et al. 2012) 
The subcellular localization patterns of tg PGC-1α remain to studied further, since 
immunostainings showed a predominant localization in close proximity of, rather 
than within, the nucleus.  
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Another aspect to be studied are the levels of active PGC-1α. Protein expression 
driven by the transgene was confirmed qualitatively in this study. However, the 
mRNA expression levels do not necessarily reflect the protein levels. Translation of 
mRNA into protein may be regulated in a way as to change the relative contribution 
of the transgene expression. Another interesting aspect for further characterization 
are the relative amounts of endogenous and transgene-driven mRNA and their 
contributions to translation into protein.  
Future studies will be aimed at quantifying PGC-1α protein levels. Furthermore, the 
activity levels of PGC-1α in the tg mice remains to be studied. As reviewed in 
chapter 1.3.1., PGC-1α activity is regulated not only on the transcriptional level, but 
on a shorter term by a host of posttranslational modifications. The most prominent 
modification mechanism is activation by deacetylation via Sirt-1. (Canto, Auwerx 
2009) For these reasons, PGC-1α  protein levels would not necessarily reflect the 
activity of PGC-1α  in a cell, and the influence and balance between activating and 
inactivating posttranslational modifications has to be taken into account.  
 
5.2.2. Partial downregulation of mitochondrial metabolic enzymes  
The expression levels of mitochondrial respiratory chain complex subunits were 
either unchanged or decreased. A pronounced downregulation was found in PGC-1α 
tg mouse Hc and Cx for complex I (NADH dehydrogenase 1α) subunit 13d, and 
complex IV (cytochrome c oxidase) subunit 7b. Additionally, citrate lyase was 
slightly underexpressed in hippocampal samples. The remaining genes related to 
ATP production were unchanged in tg mice.  
Mitochondria in brains of PGC-1α tg mice possess an enhanced metabolic capacity. 
(Mudo et al. 2012) Together with the downregulation of electron transport chain 
enzyme subunits, this may be suggesting a more efficient respiration in tg mice.  
It is, at least in hindsight, not surprising that mitochondrial respiratory chain 
complexes are downregulated in PGC-1α tg mice. The most pronounced decrease in 
mRNA levels was observed for subunits of mitochondrial electron transport chain 
complexes IV and I, known to be among the main contributors to oxidative stress. 
(Balaban, Nemoto & Finkel 2005, Nicholls 2002) It is likely that the respiratory 
chain activity undergoes adaptative changes. Merely increasing oxidative 
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phosphorylation activity via PGC-1α would be paralleled by an increase in ROS 
production and ultimately cause harm to the cells. We hypothesize that the increased 
respiratory rate control observed in mitochondria of PGC-1α tg mice is based on an 
enhanced functional state of the electron transport chain rather than an increase in 
the expression of enzymes. Via this mechanism, mitochondria can possibly improve 
efficiency of ATP production, but at the same time maintain low amounts of ROS 
production. (Puigserver et al. 1998) 
In contrast, acute overexpression of PGC-1α in cultured cells has been reported to 
entail increased expression of mitochondrial energy metabolism pathways. 
(Puigserver et al. 1998, Wu et al. 1999)  Forced overexpression of PGC-1α at high 
levels may, however, not be directly comparable to the changes in PGC-1α tg mice. 
PGC-1α levels in brain neurons of PGC-1α tg mice are enhanced, but still within a 
physiological range. (Lindholm et al. 2012) 
The long-term exposure to increased PGC-1α levels may induce feedback loops in 
neurons. This is probably the case in the PGC-1α tg mice, especially in view with the 
tight regulation of mitochondrial homeostasis mediated by PGC-1α.  
Compensatory mechanisms have been reported to be an effective response to PGC-
1α depletion in mice. (St-Pierre et al. 2006) We hypothesize that sustained PGC-1α 
overexpression equally entails changes in pathways under influence of PGC-1α. The 
slight downregulation of Sirt-1 as immediate activity regulator of PGC-1α activity 
may be a hint in the same direction. 
For future studies, this is going to be assessed by measuring age-dependent gene 
expression changes in PGC-1α tg mice. 
 
5.2.3. Upregulation of the mitochondrial antioxidant system 
The mitochondrial antioxidant glutathione reductase was upregulated in Hc and Cx 
of PGC-1α tg mice. This parallels enhanced expression of several other 
mitochondrial antioxidants shown by Mudo et al in SNc of tg mice. (Mudo et al. 
2012) This upregulation suggests an increased production of antioxidants and is in 
line with increased antioxidant expression as a response to oxidative stress, which is 
blunted upon PGC-1α depletion in murine brain neurons. (St-Pierre et al. 2006) The 
increased expression of antioxidants is likely contributing to an enhanced ability of 
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PGC-1α overexpressing neurons to scavenge ROS, contributing to an improved 
functional state of neurons.  
 
5.2.4. Expression analysis of nonmitochondrial pathways implied in Parkinson’s 
Disease  
In Hc of PGC-1α mice, decreased expression levels of some non-mitochondrial 
proteins involved in handling of dysfunctional proteins were found.  
mTOR signaling and autophagy associated proteins Rheb and Atg3 were slightly, 
but significantly underexpressed in Hc of PGC-1α tg mice. Cell cycle progression 
mediator Nedd8 did not appear to be influenced on the mRNA expression levels by 
PGC-1α overexpression. The regulator of Nedd8 activity, Uba3, was slightly 
downregulated. 
This unexpected downregulation may be due to feedback loops induced upon 
sustained PGC-1α overexpression. The translation into proteins and their activity 
remains to be studied in order to place these findings in a physiological context. 
 
5.2.5. Differential expression of GABAA receptor subunits 
In this study, gene expression determining the subunit composition of GABAA 
receptor, the predominant mediator for fast inhibitory signaling, was found to be 
altered in PGC-1 tg mice. The subunit composition, particularly of the  subunits, 
influences the subcellular localization of GABAA receptors. This, in turn, allows 
conclusions about the signaling properties. 2 subunit containing receptors are 
contributing to synaptic inhibition. (Hines et al. 2012, Wu et al. 2012) The strong 
shift towards subunit 2 expression may hint at a higher number of 2 containing 
GABAA receptors, located at synapses. Our findings suggest an enhanced production 
of receptors mediating fast, synaptic inhibition in the PGC-1 tg mice. 
GABAergic signaling pathways are impaired with aging and changes in GABAA 
receptor subunit composition have been reported in connection with several 
neuropathologies and neurodegenerative diseases. (Elstner et al. 2011, Luchetti, 
Huitinga & Swaab 2011) 
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Moreover, PGC-1α is strongly expressed in GABAergic interneurons throughout the 
rat brain during development. It has been suggested that PGC-1α expression during 
development mediates mitochondrial biogenesis and activity, which is important for 
formation of synaptic contacts. Furthermore, it has been proposed that PGC-1 acts 
on GABAergic neurons by influencing glucose metabolism. (Cowell, Blake & 
Russell 2007) In line with this, our findings suggest a link between neuroprotection 
and the expression of GABAA receptor subunits. Our findings imply that an 
increased number of neurons are targeted by GABAergic synaptic inhibitory 
signaling. The IHC staining results indicate an increase in the number of Gabra2 
expressing neurons. A conceivable explanation is that PGC-1α possibly enhances the 
functional state of GABAergic neurons and their interactions via synaptic signals by 
promoting the expression of GABAA receptors.  These findings may imply 
protection against glutamate mediated excitotoxicity via increased inhibitory 
signaling. Possibly, this is related to the role of PGC-1 regulating vulnerability of 
neurons towards excitotoxicity. (Cowell, Blake & Russell 2007, Hines et al. 2012, 
Lucas et al. 2010, Soriano et al. 2011) 
 
5.3. Conclusions and future prospects 
The aim of this Master’s thesis study was to measure gene expression on the mRNA 
levels for a set of genes and identify gene networks with differentially regulated 
expression patterns in PGC-1α tg mice as compared to wt controls.  
PGC-1α overexpression in tg mice was confirmed on the mRNA level, and 
translation to protein was confirmed. 
Our results show that PGC-1α overexpression in brain neurons is associated with 
significant changes in gene expression patterns. This concerns mitochondrial 
oxidative metabolism and antioxidant systems. Further, non-mitochondrial pathways 
showing alterations in gene expression in association with PGC-1α overexpression 
were GABAergic receptor signaling, autophagy, and contributors to cell cycle 
regulation. 
In keeping with previous studies of the physiology of brain neurons of PGC-1α  tg 
mice, our finding suggest that PGC-1α overexpression may cause gene expression 
changes that enhance the functional state of hippocampal and cortical neurons.  
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Our results suggest that PGC-1α may be able to alter gene expression networks in a 
way to enhance mitochondrial functional state and confer protection against 
oxidative stress and energetic failure. 
In accordance with previous reports, the studies presented in this Master’s thesis 
contribute to forming a coherent picture of the neuroprotective influences mediated 
by PGC-1α controlled gene expression networks. PGC-1α and related coactivators 
on the one hand are able to mediate responses to increased energetic demands and to 
maintain a level of energy supply by regulating oxidative phosphorylation. On the 
other hand, PGC-1α also is involved in scavenging the increased amounts of 
oxidants that are being generated as a byproduct of enhanced metabolic activity, 
ensuring a stable energetic and oxidative cellular homeostasis. (Wu et al. 1999, Rohas 
et al. 2007) 
Future directions for this project will predominantly be aimed at a more thorough 
characterization of the PGC-1α tg mouse line in the focus of this Master’s Thesis 
study. As a first step, PGC-1α protein expression and activity levels have to be 
studied. For future studies, it will be important to determine whether gene expression 
patterns are paralleled by translation protein, how the dynamics of the processes and 
mitochondrial physiology are affected.  
The findings reported here reflect the complex interactions in which PGC-1α is 
involved. This equally concerns regulation of PGC-1α expression and activity, as 
interactions between the PGC-1α regulated processes. The complexity of the PGC-
1α regulated interactions that maintain cellular homeostasis shows how tightly 
regulated and thoroughly maintained these pathways are.  
In view with a role of PGC-1α in neuroprotection, it is clear that neurodegeneration, 
and particularly PD, is the result of a host of disturbances in multiple cellular 
functions and their mutual interactions. For this reason, it is certainly difficult to stop 
pathogenesis by intervening at one single point. For neuroprotective treatments, it is 
more feasible to halt disease progression by targeting multiple pathways 
simultaneously. 
PGC-1α may be a suitable axis of regulation, being is the pivotal point translating a 
number of environmental signals into changes in several pathways that ultimately all 
contribute to maintain intracellular homeostasis. Furthermore, PGC-1α can relatively 
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easily be modulated by small molecular compounds, such as the polyphenol 
resveratrol (RSV). (Lagouge et al. 2006) 
Screening for mild dysregulations in PD affected pathways early in disease 
progression might be used as an indicator for starting neuroprotective treatment. 
(Zheng et al. 2010) Subsequently, boosting PGC-1α activity may influence a number 
of pathways and positively affect the functional state of brain neurons to stabilize the 
functional state of predominantly, but not only, the nigrostriatal system. Additional 
brain areas have been implicated in PD, such as the Hc, thought to be having a role 
in neuroregeneration. (Marxreiter, Regensburger & Winkler 2013) 
By pharmacologically targeting PGC-1α and enhancing the neuroprotective effects 
via PGC-1α controlled pathways, neurons could be protected from degeneration, and 
possibly the disease progression could be slowed. On the long term, this can 
contribute to establishing a curative treatment for PD. 
 
83 
 
References 
Abou-Sleiman, P.M., Muqit, M.M. & Wood, N.W. 2006, "Expanding insights of mitochondrial 
dysfunction in Parkinson's disease", Nature reviews.Neuroscience, vol. 7, no. 3, pp. 207-
219.  
Andrews, Z.B., Diano, S. & Horvath, T.L. 2005, "Mitochondrial uncoupling proteins in the CNS: 
in support of function and survival", Nature reviews.Neuroscience, vol. 6, no. 11, pp. 829-
840.  
Arduino, D.M., Esteves, A.R., Oliveira, C.R. & Cardoso, S.M. 2010, "Mitochondrial metabolism 
modulation: a new therapeutic approach for Parkinson's disease", CNS & neurological 
disorders drug targets, vol. 9, no. 1, pp. 105-119.  
Atlante, A., Calissano, P., Bobba, A., Giannattasio, S., Marra, E. & Passarella, S. 2001, 
"Glutamate neurotoxicity, oxidative stress and mitochondria", FEBS letters, vol. 497, no. 1, 
pp. 1-5.  
Balaban, R.S., Nemoto, S. & Finkel, T. 2005, "Mitochondria, oxidants, and aging", Cell, vol. 
120, no. 4, pp. 483-495.  
Beal, M.F. 2005, "Mitochondria take center stage in aging and neurodegeneration", Annals of 
Neurology, vol. 58, no. 4, pp. 495-505.  
Beal, M.F. 2003, "Mitochondria, oxidative damage, and inflammation in Parkinson's disease", 
Annals of the New York Academy of Sciences, vol. 991, pp. 120-131.  
Beal, M.F. 1998, "Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis", Annals of 
Neurology, vol. 44, no. 3 Suppl 1, pp. S110-4.  
Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-Osuna, M., Panov, A.V. & Greenamyre, J.T. 
2000, "Chronic systemic pesticide exposure reproduces features of Parkinson's disease", 
Nature neuroscience, vol. 3, no. 12, pp. 1301-1306.  
Blandini, F. 2010, "An update on the potential role of excitotoxicity in the pathogenesis of 
Parkinson's disease", Functional neurology, vol. 25, no. 2, pp. 65-71.  
Brotchie, J. & Fitzer-Attas, C. 2009, "Mechanisms compensating for dopamine loss in early 
Parkinson disease", Neurology, vol. 72, no. 7 Suppl, pp. S32-8.  
Canto, C. & Auwerx, J. 2009, "PGC-1alpha, SIRT1 and AMPK, an energy sensing network that 
controls energy expenditure", Current opinion in lipidology, vol. 20, no. 2, pp. 98-105.  
Caroni, P. 1997, "Overexpression of growth-associated proteins in the neurons of adult 
transgenic mice", Journal of neuroscience methods, vol. 71, no. 1, pp. 3-9.  
Chypre, M., Zaidi, N. & Smans, K. 2012, "ATP-citrate lyase: a mini-review", Biochemical and 
biophysical research communications, vol. 422, no. 1, pp. 1-4.  
Clark, J. & Simon, D.K. 2009, "Transcribe to survive: transcriptional control of antioxidant 
defense programs for neuroprotection in Parkinson's disease", Antioxidants & redox 
signaling, vol. 11, no. 3, pp. 509-528.  
Cohen, G. 2000, "Oxidative stress, mitochondrial respiration, and Parkinson's disease", Annals of 
the New York Academy of Sciences, vol. 899, pp. 112-120.  
Cohen, G., Farooqui, R. & Kesler, N. 1997, "Parkinson disease: a new link between monoamine 
oxidase and mitochondrial electron flow", Proceedings of the National Academy of 
Sciences of the United States of America, vol. 94, no. 10, pp. 4890-4894.  
Cohen, G. & Kesler, N. 1999a, "Monoamine oxidase and mitochondrial respiration", Journal of 
neurochemistry, vol. 73, no. 6, pp. 2310-2315.  
Cohen, G. & Kesler, N. 1999b, "Monoamine oxidase inhibits mitochondrial respiration", Annals 
of the New York Academy of Sciences, vol. 893, pp. 273-278.  
84 
 
Cowell, R.M., Blake, K.R. & Russell, J.W. 2007, "Localization of the transcriptional coactivator 
PGC-1alpha to GABAergic neurons during maturation of the rat brain", The Journal of 
comparative neurology, vol. 502, no. 1, pp. 1-18.  
Dauer, W. & Przedborski, S. 2003, "Parkinson's disease: mechanisms and models", Neuron, vol. 
39, no. 6, pp. 889-909.  
Dexter, D.T. & Jenner, P. 2013, "Parkinson disease: from pathology to molecular disease 
mechanisms", Free radical biology & medicine, .  
Dorak, M.T. 2006, Real-time PCR, Taylor & Francis, New York, NY.  
Draghici, S., Khatri, P., Eklund, A.C. & Szallasi, Z. 2006, "Reliability and reproducibility issues 
in DNA microarray measurements", Trends in genetics : TIG, vol. 22, no. 2, pp. 101-109.  
Duchen, M.R. 2004, "Mitochondria in health and disease: perspectives on a new mitochondrial 
biology", Molecular aspects of medicine, vol. 25, no. 4, pp. 365-451.  
Elstner, M., Morris, C.M., Heim, K., Bender, A., Mehta, D., Jaros, E., Klopstock, T., Meitinger, 
T., Turnbull, D.M. & Prokisch, H. 2011, "Expression analysis of dopaminergic neurons in 
Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to 
cell death", Acta Neuropathologica, vol. 122, no. 1, pp. 75-86.  
Esterbauer, H., Oberkofler, H., Krempler, F. & Patsch, W. 1999, "Human peroxisome 
proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, 
genomic organization, chromosomal localization, and tissue expression", Genomics, vol. 
62, no. 1, pp. 98-102.  
Fernandez-Marcos, P.J. & Auwerx, J. 2011, "Regulation of PGC-1alpha, a nodal regulator of 
mitochondrial biogenesis", The American Journal of Clinical Nutrition, vol. 93, no. 4, pp. 
884S-90.  
Gong, L. & Yeh, E.T. 1999, "Identification of the activating and conjugating enzymes of the 
NEDD8 conjugation pathway", The Journal of biological chemistry, vol. 274, no. 17, pp. 
12036-12042.  
Hines, R.M., Davies, P.A., Moss, S.J. & Maguire, J. 2012, "Functional regulation of GABAA 
receptors in nervous system pathologies", Current opinion in neurobiology, vol. 22, no. 3, 
pp. 552-558.  
Holopainen, I.E. & Lauren, H.B. 2003, "Neuronal activity regulates GABAA receptor subunit 
expression in organotypic hippocampal slice cultures", Neuroscience, vol. 118, no. 4, pp. 
967-974.  
Imai, S., Johnson, F.B., Marciniak, R.A., McVey, M., Park, P.U. & Guarente, L. 2000, "Sir2: an 
NAD-dependent histone deacetylase that connects chromatin silencing, metabolism, and 
aging", Cold Spring Harbor symposia on quantitative biology, vol. 65, pp. 297-302.  
Jankovic, J. 2008, "Parkinson's disease: clinical features and diagnosis", Journal of neurology, 
neurosurgery, and psychiatry, vol. 79, no. 4, pp. 368-376.  
Jeninga, E.H., Schoonjans, K. & Auwerx, J. 2010, "Reversible acetylation of PGC-1: connecting 
energy sensors and effectors to guarantee metabolic flexibility", Oncogene, vol. 29, no. 33, 
pp. 4617-4624.  
Jenner, P. 2004, "Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors 
in Parkinson's disease", Neurology, vol. 63, no. 7 Suppl 2, pp. S13-22.  
Jenner, P. 2003, "Oxidative stress in Parkinson's disease", Annals of Neurology, vol. 53 Suppl 3, 
pp. S26-36; discussion S36-8.  
Jenner, P. & Olanow, C.W. 2006, "The pathogenesis of cell death in Parkinson's disease", 
Neurology, vol. 66, no. 10 Suppl 4, pp. S24-36.  
85 
 
Kamitani, T., Kito, K., Nguyen, H.P. & Yeh, E.T. 1997, "Characterization of NEDD8, a 
developmentally down-regulated ubiquitin-like protein", The Journal of biological 
chemistry, vol. 272, no. 45, pp. 28557-28562.  
Kelly, D.P. & Scarpulla, R.C. 2004, "Transcriptional regulatory circuits controlling 
mitochondrial biogenesis and function", Genes & development, vol. 18, no. 4, pp. 357-368.  
Kim, I., Rodriguez-Enriquez, S. & Lemasters, J.J. 2007, "Selective degradation of mitochondria 
by mitophagy", Archives of Biochemistry and Biophysics, vol. 462, no. 2, pp. 245-253.  
Kowaltowski, A.J., de Souza-Pinto, N.C., Castilho, R.F. & Vercesi, A.E. 2009, "Mitochondria 
and reactive oxygen species", Free radical biology & medicine, vol. 47, no. 4, pp. 333-343.  
Kukidome, D., Nishikawa, T., Sonoda, K., Imoto, K., Fujisawa, K., Yano, M., Motoshima, H., 
Taguchi, T., Matsumura, T. & Araki, E. 2006, "Activation of AMP-activated protein kinase 
reduces hyperglycemia-induced mitochondrial reactive oxygen species production and 
promotes mitochondrial biogenesis in human umbilical vein endothelial cells", Diabetes, 
vol. 55, no. 1, pp. 120-127.  
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, 
N., Milne, J., Lambert, P., Elliott, P., Geny, B., Laakso, M., Puigserver, P. & Auwerx, J. 
2006, "Resveratrol improves mitochondrial function and protects against metabolic disease 
by activating SIRT1 and PGC-1alpha", Cell, vol. 127, no. 6, pp. 1109-1122.  
Lee, J., Giordano, S. & Zhang, J. 2012, "Autophagy, mitochondria and oxidative stress: cross-
talk and redox signalling", The Biochemical journal, vol. 441, no. 2, pp. 523-540.  
Leone, T.C., Lehman, J.J., Finck, B.N., Schaeffer, P.J., Wende, A.R., Boudina, S., Courtois, M., 
Wozniak, D.F., Sambandam, N., Bernal-Mizrachi, C., Chen, Z., Holloszy, J.O., Medeiros, 
D.M., Schmidt, R.E., Saffitz, J.E., Abel, E.D., Semenkovich, C.F. & Kelly, D.P. 2005, 
"PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle 
dysfunction, abnormal weight control and hepatic steatosis", PLoS biology, vol. 3, no. 4, pp. 
e101.  
Lin, J., Handschin, C. & Spiegelman, B.M. 2005, "Metabolic control through the PGC-1 family 
of transcription coactivators", Cell metabolism, vol. 1, no. 6, pp. 361-370.  
Lin, J., Wu, P.H., Tarr, P.T., Lindenberg, K.S., St-Pierre, J., Zhang, C.Y., Mootha, V.K., Jager, 
S., Vianna, C.R., Reznick, R.M., Cui, L., Manieri, M., Donovan, M.X., Wu, Z., Cooper, 
M.P., Fan, M.C., Rohas, L.M., Zavacki, A.M., Cinti, S., Shulman, G.I., Lowell, B.B., 
Krainc, D. & Spiegelman, B.M. 2004, "Defects in adaptive energy metabolism with CNS-
linked hyperactivity in PGC-1alpha null mice", Cell, vol. 119, no. 1, pp. 121-135.  
Lin, M.T. & Beal, M.F. 2006, "Mitochondrial dysfunction and oxidative stress in 
neurodegenerative diseases", Nature, vol. 443, no. 7113, pp. 787-795.  
Lindholm, D., Eriksson, O., Makela, J., Belluardo, N. & Korhonen, L. 2012, "PGC-1alpha: a 
master gene that is hard to master", Cellular and molecular life sciences : CMLS, vol. 69, 
no. 15, pp. 2465-2468.  
Livak, K.J. & Schmittgen, T.D. 2001, "Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta C(T)) Method", Methods (San Diego, Calif.), vol. 
25, no. 4, pp. 402-408.  
Lotharius, J. & Brundin, P. 2002, "Pathogenesis of Parkinson's disease: dopamine, vesicles and 
alpha-synuclein", Nature reviews.Neuroscience, vol. 3, no. 12, pp. 932-942.  
Lucas, E.K., Markwardt, S.J., Gupta, S., Meador-Woodruff, J.H., Lin, J.D., Overstreet-Wadiche, 
L. & Cowell, R.M. 2010, "Parvalbumin deficiency and GABAergic dysfunction in mice 
lacking PGC-1alpha", The Journal of neuroscience : the official journal of the Society for 
Neuroscience, vol. 30, no. 21, pp. 7227-7235.  
Luchetti, S., Huitinga, I. & Swaab, D.F. 2011, "Neurosteroid and GABA-A receptor alterations 
in Alzheimer's disease, Parkinson's disease and multiple sclerosis", Neuroscience, vol. 191, 
pp. 6-21.  
86 
 
Ma, D., Li, S., Lucas, E.K., Cowell, R.M. & Lin, J.D. 2010, "Neuronal inactivation of 
peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) 
protects mice from diet-induced obesity and leads to degenerative lesions", The Journal of 
biological chemistry, vol. 285, no. 50, pp. 39087-39095.  
Marxreiter, F., Regensburger, M. & Winkler, J. 2013, "Adult neurogenesis in Parkinson's 
disease", Cellular and molecular life sciences : CMLS, vol. 70, no. 3, pp. 459-473.  
Meredith, G.E., Totterdell, S., Beales, M. & Meshul, C.K. 2009, "Impaired glutamate 
homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's 
disease", Experimental neurology, vol. 219, no. 1, pp. 334-340.  
Meredith, G.E., Totterdell, S., Potashkin, J.A. & Surmeier, D.J. 2008, "Modeling PD 
pathogenesis in mice: advantages of a chronic MPTP protocol", Parkinsonism & related 
disorders, vol. 14 Suppl 2, pp. S112-5.  
Moore, D.J., West, A.B., Dawson, V.L. & Dawson, T.M. 2005, "Molecular pathophysiology of 
Parkinson's disease", Annual Review of Neuroscience, vol. 28, pp. 57-87.  
Mootha, V.K., Handschin, C., Arlow, D., Xie, X., St Pierre, J., Sihag, S., Yang, W., Altshuler, 
D., Puigserver, P., Patterson, N., Willy, P.J., Schulman, I.G., Heyman, R.A., Lander, E.S. & 
Spiegelman, B.M. 2004, "Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative 
phosphorylation gene expression that is altered in diabetic muscle", Proceedings of the 
National Academy of Sciences of the United States of America, vol. 101, no. 17, pp. 6570-
6575.  
Mudo, G., Makela, J., Di Liberto, V., Tselykh, T.V., Olivieri, M., Piepponen, P., Eriksson, O., 
Malkia, A., Bonomo, A., Kairisalo, M., Aguirre, J.A., Korhonen, L., Belluardo, N. & 
Lindholm, D. 2012, "Transgenic expression and activation of PGC-1alpha protect 
dopaminergic neurons in the MPTP mouse model of Parkinson's disease", Cellular and 
molecular life sciences : CMLS, vol. 69, no. 7, pp. 1153-1165.  
Murphy, A.N., Fiskum, G. & Beal, M.F. 1999, "Mitochondria in neurodegeneration: bioenergetic 
function in cell life and death", Journal of cerebral blood flow and metabolism : official 
journal of the International Society of Cerebral Blood Flow and Metabolism, vol. 19, no. 3, 
pp. 231-245.  
Nicholls, D.G. 2002, "Mitochondrial function and dysfunction in the cell: its relevance to aging 
and aging-related disease", The international journal of biochemistry & cell biology, vol. 
34, no. 11, pp. 1372-1381.  
Nicholls, D.G., Johnson-Cadwell, L., Vesce, S., Jekabsons, M. & Yadava, N. 2007, 
"Bioenergetics of mitochondria in cultured neurons and their role in glutamate 
excitotoxicity", Journal of neuroscience research, vol. 85, no. 15, pp. 3206-3212.  
Nunnari, J. & Suomalainen, A. 2012, "Mitochondria: in sickness and in health", Cell, vol. 148, 
no. 6, pp. 1145-1159.  
Pfaffl, M.W. 2001, "A new mathematical model for relative quantification in real-time RT-
PCR", Nucleic acids research, vol. 29, no. 9, pp. e45.  
Poewe, W. 2008, "Non-motor symptoms in Parkinson's disease", European journal of neurology 
: the official journal of the European Federation of Neurological Societies, vol. 15 Suppl 1, 
pp. 14-20.  
Przedborski, S., Tieu, K., Perier, C. & Vila, M. 2004, "MPTP as a mitochondrial neurotoxic 
model of Parkinson's disease", Journal of Bioenergetics and Biomembranes, vol. 36, no. 4, 
pp. 375-379.  
Puigserver, P. & Spiegelman, B.M. 2003, "Peroxisome proliferator-activated receptor-gamma 
coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator", 
Endocrine reviews, vol. 24, no. 1, pp. 78-90.  
87 
 
Puigserver, P., Wu, Z., Park, C.W., Graves, R., Wright, M. & Spiegelman, B.M. 1998, "A cold-
inducible coactivator of nuclear receptors linked to adaptive thermogenesis", Cell, vol. 92, 
no. 6, pp. 829-839.  
Purves, D. 2012, Neuroscience, 5th edn, Sinauer Associates, Sunderland, MA.  
Rohas, L.M., St-Pierre, J., Uldry, M., Jager, S., Handschin, C. & Spiegelman, B.M. 2007, "A 
fundamental system of cellular energy homeostasis regulated by PGC-1alpha", Proceedings 
of the National Academy of Sciences of the United States of America, vol. 104, no. 19, pp. 
7933-7938.  
Scarpulla, R.C. 2011, "Metabolic control of mitochondrial biogenesis through the PGC-1 family 
regulatory network", Biochimica et biophysica acta, vol. 1813, no. 7, pp. 1269-1278.  
Scarpulla, R.C. 2006, "Nuclear control of respiratory gene expression in mammalian cells", 
Journal of cellular biochemistry, vol. 97, no. 4, pp. 673-683.  
Scarpulla, R.C. 2002, "Nuclear activators and coactivators in mammalian mitochondrial 
biogenesis", Biochimica et biophysica acta, vol. 1576, no. 1-2, pp. 1-14.  
Schapira, A.H. 2009, "Etiology and pathogenesis of Parkinson disease", Neurologic clinics, vol. 
27, no. 3, pp. 583-603, v.  
Schapira, A.H. 2008, "Mitochondria in the aetiology and pathogenesis of Parkinson's disease", 
Lancet neurology, vol. 7, no. 1, pp. 97-109.  
Schapira, A.H., Agid, Y., Barone, P., Jenner, P., Lemke, M.R., Poewe, W., Rascol, O., 
Reichmann, H. & Tolosa, E. 2009, "Perspectives on recent advances in the understanding 
and treatment of Parkinson's disease", European journal of neurology : the official journal 
of the European Federation of Neurological Societies, vol. 16, no. 10, pp. 1090-1099.  
Schmittgen, T.D. & Livak, K.J. 2008, "Analyzing real-time PCR data by the comparative C(T) 
method", Nature protocols, vol. 3, no. 6, pp. 1101-1108.  
Schon, E.A. & Przedborski, S. 2011, "Mitochondria: the next (neurode)generation", Neuron, vol. 
70, no. 6, pp. 1033-1053.  
Schulz, J.B., Lindenau, J., Seyfried, J. & Dichgans, J. 2000, "Glutathione, oxidative stress and 
neurodegeneration", European journal of biochemistry / FEBS, vol. 267, no. 16, pp. 4904-
4911.  
Soriano, F.X., Leveille, F., Papadia, S., Bell, K.F., Puddifoot, C. & Hardingham, G.E. 2011, 
"Neuronal activity controls the antagonistic balance between peroxisome proliferator-
activated receptor-gamma coactivator-1alpha and silencing mediator of retinoic acid and 
thyroid hormone receptors in regulating antioxidant defenses", Antioxidants & redox 
signaling, vol. 14, no. 8, pp. 1425-1436.  
Spina, M.B. & Cohen, G. 1989, "Dopamine turnover and glutathione oxidation: implications for 
Parkinson disease", Proceedings of the National Academy of Sciences of the United States 
of America, vol. 86, no. 4, pp. 1398-1400.  
Srinivasan, S. & Avadhani, N.G. 2012, "Cytochrome c oxidase dysfunction in oxidative stress", 
Free radical biology & medicine, vol. 53, no. 6, pp. 1252-1263.  
St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J.M., Rhee, J., Jager, S., Handschin, C., Zheng, K., 
Lin, J., Yang, W., Simon, D.K., Bachoo, R. & Spiegelman, B.M. 2006, "Suppression of 
reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators", 
Cell, vol. 127, no. 2, pp. 397-408.  
St-Pierre, J., Lin, J., Krauss, S., Tarr, P.T., Yang, R., Newgard, C.B. & Spiegelman, B.M. 2003, 
"Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 
1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells", The Journal of biological 
chemistry, vol. 278, no. 29, pp. 26597-26603.  
88 
 
Surmeier, D.J., Guzman, J.N., Sanchez-Padilla, J. & Goldberg, J.A. 2011, "The origins of 
oxidant stress in Parkinson's disease and therapeutic strategies", Antioxidants & redox 
signaling, vol. 14, no. 7, pp. 1289-1301.  
Thomas, B. & Beal, M.F. 2011, "Molecular insights into Parkinson's disease", F1000 medicine 
reports, vol. 3, pp. 7-7. Epub 2011 Apr 1.  
Thomas, B. & Beal, M.F. 2007, "Parkinson's disease", Human molecular genetics, vol. 16 Spec 
No. 2, pp. R183-94.  
Tritos, N.A., Mastaitis, J.W., Kokkotou, E.G., Puigserver, P., Spiegelman, B.M. & Maratos-
Flier, E. 2003, "Characterization of the peroxisome proliferator activated receptor 
coactivator 1 alpha (PGC 1alpha) expression in the murine brain", Brain research, vol. 961, 
no. 2, pp. 255-260.  
Tsunemi, T. & La Spada, A.R. 2012, "PGC-1alpha at the intersection of bioenergetics regulation 
and neuron function: from Huntington's disease to Parkinson's disease and beyond", 
Progress in neurobiology, vol. 97, no. 2, pp. 142-151.  
Turrens, J.F. 2003, "Mitochondrial formation of reactive oxygen species", The Journal of 
physiology, vol. 552, no. Pt 2, pp. 335-344.  
Valle, I., Alvarez-Barrientos, A., Arza, E., Lamas, S. & Monsalve, M. 2005, "PGC-1alpha 
regulates the mitochondrial antioxidant defense system in vascular endothelial cells", 
Cardiovascular research, vol. 66, no. 3, pp. 562-573.  
VanGuilder, H.D., Vrana, K.E. & Freeman, W.M. 2008, "Twenty-five years of quantitative PCR 
for gene expression analysis", BioTechniques, vol. 44, no. 5, pp. 619-626.  
Vidal, M., Morris, R., Grosveld, F. & Spanopoulou, E. 1990, "Tissue-specific control elements 
of the Thy-1 gene", The EMBO journal, vol. 9, no. 3, pp. 833-840.  
Wang, Q., Yu, S., Simonyi, A., Sun, G.Y. & Sun, A.Y. 2005, "Kainic acid-mediated 
excitotoxicity as a model for neurodegeneration", Molecular neurobiology, vol. 31, no. 1-3, 
pp. 3-16.  
Wareski, P., Vaarmann, A., Choubey, V., Safiulina, D., Liiv, J., Kuum, M. & Kaasik, A. 2009, 
"PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons", The Journal 
of biological chemistry, vol. 284, no. 32, pp. 21379-21385.  
Winklhofer, K.F. & Haass, C. 2010, "Mitochondrial dysfunction in Parkinson's disease", 
Biochimica et biophysica acta, vol. 1802, no. 1, pp. 29-44.  
Wu, X., Wu, Z., Ning, G., Guo, Y., Ali, R., Macdonald, R.L., De Blas, A.L., Luscher, B. & 
Chen, G. 2012, "gamma-Aminobutyric acid type A (GABAA) receptor alpha subunits play 
a direct role in synaptic versus extrasynaptic targeting", The Journal of biological 
chemistry, vol. 287, no. 33, pp. 27417-27430.  
Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., Cinti, S., 
Lowell, B., Scarpulla, R.C. & Spiegelman, B.M. 1999, "Mechanisms controlling 
mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1", 
Cell, vol. 98, no. 1, pp. 115-124.  
Zheng, B., Liao, Z., Locascio, J.J., Lesniak, K.A., Roderick, S.S., Watt, M.L., Eklund, A.C., 
Zhang-James, Y., Kim, P.D., Hauser, M.A., Grunblatt, E., Moran, L.B., Mandel, S.A., 
Riederer, P., Miller, R.M., Federoff, H.J., Wullner, U., Papapetropoulos, S., Youdim, M.B., 
Cantuti-Castelvetri, I., Young, A.B., Vance, J.M., Davis, R.L., Hedreen, J.C., Adler, C.H., 
Beach, T.G., Graeber, M.B., Middleton, F.A., Rochet, J.C., Scherzer, C.R. & Global PD 
Gene Expression (GPEX) Consortium 2010, "PGC-1alpha, a potential therapeutic target for 
early intervention in Parkinson's disease", Science translational medicine, vol. 2, no. 52, pp. 
52ra73.  
Zigmond, M.J., Hastings, T.G. & Perez, R.G. 2002, "Increased dopamine turnover after partial 
loss of dopaminergic neurons: compensation or toxicity?", Parkinsonism & related 
disorders, vol. 8, no. 6, pp. 389-393.  
89 
 
Acknowledgements 
This Master’s Thesis study was conducted at the Department of Biochemistry and 
Developmental Biology, Institute of Biomedicine, University of Helsinki, and in part 
at Minerva Foundation Institute for Medical Research. 
I would like to thank Prof. Dan Lindholm for the opportunity to work in his group 
and to be part of this interesting project. I am very grateful for supervision and 
endless optimism during this Master’s Thesis project. 
Furthermore, I would like to thank Johanna Mäkelä for support and practical advice, 
as well as for many helpful discussions about my project, antioxidants, and 
chocolate, and for taking care of my NAD
+
 levels. 
Dr. Tho Huu Ho has been of invaluable help with any qPCR related questions. I am 
very grateful for lots of incredibly friendly advice. 
I would like to thank my family and friends, who are absolutely wunderbar, for 
always being there for me and making life so worth living. Especially, I would like 
to thank my parents for their love and support throughout the years, and for always 
believing in me and my plans. 
 
 
Figure 30  Love for PGC-1α.  
Immunostaining for PGC-1α in Hc of tg mice 
 
 
